



GB03/005091



INVESTOR IN PEOPLE

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ


RECEIVED
28 JAN 2004
WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed

Dated

19 December 2003

Patent Act 1977
(Rule 16)



Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference 100856-2

2. Patent application number 0310828.9
(The Patent Office will fill in this part)

0310828.9

12MAY03 E806456-1 002934
P01/7700 0.00-0310828.9

3. Full name, address and postcode of the or of each applicant (underline all surnames)
AstraZeneca AB
SE-151 85 Sodertalje
Sweden

Patents ADP number (if you know it) 07892448003

If the applicant is a corporate body, give the country/state of its incorporation Sweden

4. Title of the invention
CHEMICAL COMPOUNDS

5. Name of your agent (if you have one) Kevin BILL
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)
AstraZeneca UK Limited
Global Intellectual Property
Mereside, Alderley Park
Macclesfield,
Cheshire SK10 4TG

Patents ADP number (if you know it)

04469847003

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country	Priority application number (if you know it)	Date of filing (day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:
a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.
See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

64

Claim(s)

18

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date 09 MAY 2000

Jennifer BENNETT, Authorised Signatory

12. Name and daytime telephone number of person to contact in the United Kingdom

Shirley Douglas - 01625 510057

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

CHEMICAL COMPOUNDS

The present invention relates to antibiotic compounds and in particular to antibiotic compounds containing substituted oxazolidinone rings. This invention further relates to processes for their preparation, to intermediates useful in their preparation, to their use as therapeutic agents and to pharmaceutical compositions containing them.

The international microbiological community continues to express serious concern that the evolution of antibiotic resistance could result in strains against which currently available antibacterial agents will be ineffective. In general, bacterial pathogens may be classified as either Gram-positive or Gram-negative pathogens. Antibiotic compounds with effective activity against both Gram-positive and Gram-negative pathogens are generally regarded as having a broad spectrum of activity. The compounds of the present invention are regarded as effective against both Gram-positive and certain Gram-negative pathogens.


Gram-positive pathogens, for example Staphylococci, Enterococci, Streptococci and mycobacteria, are particularly important because of the development of resistant strains which are both difficult to treat and difficult to eradicate from the hospital environment once established. Examples of such strains are methicillin resistant staphylococcus (MRSA), methicillin resistant coagulase negative staphylococci (MRCNS), penicillin resistant Streptococcus pneumoniae and multiply resistant Enterococcus faecium.

The major clinically effective antibiotic for treatment of such resistant Gram-positive pathogens is vancomycin. Vancomycin is a glycopeptide and is associated with various toxicities including nephrotoxicity. Furthermore, and most importantly, antibacterial resistance to vancomycin and other glycopeptides is also appearing. This resistance is increasing at a steady rate rendering these agents less and less effective in the treatment of Gram-positive pathogens. There is also now increasing resistance appearing towards agents such as β -lactams, quinolones and macrolides used for the treatment of upper respiratory tract infections, also caused by certain Gram negative strains including H.influenzae and M.catarrhalis.

Certain antibacterial compounds containing an oxazolidinone ring have been described in the art (for example, Walter A. Gregory et al in J.Med.Chem. 1990, 33, 2569-2578 and 1989, 32(8), 1673-81; Chung-Ho Park et al in J.Med.Chem. 1992, 35, 1156-1165). Bacterial resistance to known antibacterial agents may develop, for example, by (i) the evolution of active binding sites in the bacteria rendering a previously active pharmacophore less effective


or redundant, and/or (ii) the evolution of means to chemically deactivate a given pharmacophore, and/or (iii) the evolution of efflux pathways. Therefore, there remains an ongoing need to find new antibacterial agents with a favourable pharmacological profile, in particular for compounds containing new, more potent, pharmacophores.

- 5 Accordingly the present invention provides a compound of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof,



10

wherein C is selected from D and E,



wherein in D and E the phenyl ring is attached to the oxazolidinone in (I);

R₁b is HET1 or HET2, wherein

- 15 i) HET1 is an N-linked 5-membered, fully or partially unsaturated heterocyclic ring, containing either (i) 1 to 3 further nitrogen heteroatoms or (ii) a further heteroatom selected from O and S together with an optional further nitrogen heteroatom; which ring is optionally substituted on a C atom, other than a C atom adjacent to the linking N atom, by an oxo or thioxo group; and/or which ring is optionally substituted on any available C atom, other than a
- 20 C atom adjacent to the linking N atom, by a substituent selected from RT as hereinafter defined and/or on an available nitrogen atom, other than a N atom adjacent to the linking N atom, (provided that the ring is not thereby quaternised) by (1-4C)alkyl;
- ii) HET2 is an N-linked 6-membered di-hydro-heteroaryl ring containing up to three nitrogen heteroatoms in total (including the linking heteroatom), which ring is substituted on a suitable
- 25 C atom, other than a C atom adjacent to the linking N atom, by oxo or thioxo and/or which ring is optionally substituted on any available C atom, other than a C atom adjacent to the

linking N atom, by one or two substituents independently selected from RT as hereinafter defined and/or on an available nitrogen atom, other than a N atom adjacent to the linking N atom, (provided that the ring is not thereby quaternised) by (1-4C)alkyl;

RT is selected from a substituent from the group:

5 (RTa1) hydrogen, halogen, (1-4C)alkoxy, (2-4C)alkenyloxy, (2-4C)alkenyl,

(2-4C)alkynyl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, (1-4C)alkylthio, amino, azido, cyano and nitro; or

(RTa2) (1-4C)alkylamino, di-(1-4C)alkylamino, and (2-4C)alkenylamino;

or RT is selected from the group

10 (RTb1) (1-4C)alkyl group which is optionally substituted by one substituent selected from hydroxy, (1-4C)alkoxy, (1-4C)alkylthio, cyano and azido; or

(RTb2) (1-4C)alkyl group which is optionally substituted by one substituent selected from (2-4C)alkenyloxy, (3-6C)cycloalkyl, and (3-6C)cycloalkenyl;

or RT is selected from the group

15 (RTc) a fully saturated 4-membered monocyclic ring containing 1 or 2 heteroatoms independently selected from O, N and S (optionally oxidised), and linked via a ring nitrogen or carbon atom;

and wherein at each occurrence of an RT substituent containing an alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl moiety in (RTa1) or (RTa2), (RTb1) or (RTb2), or (RTc) each

20 such moiety is optionally substituted on an available carbon atom with one, two, three or more substituents independently selected from F, Cl, Br, OH and CN;

R_{2a} and R_{6a} are independently selected from H, CF₃, OMe, SMe, Me and Et;

R_{2b} and R_{6b} are independently selected from H, F, Cl, CF₃, OMe, SMe, Me and Et;

R_{3a} is selected from H, (1-4C)alkyl, cyano, Br, F, Cl, OH, (1-4C)alkoxy, -S(O)_n(1-4C)alkyl

25 (wherein n = 0, 1, or 2), amino, (1-4C)alkylcarbonylamino, nitro, -CHO, -CO(1-4C)alkyl, -CONH₂ and -CONH(1-4C)alkyl;

R₄ is selected from R_{4a} and R_{4b} wherein

R_{4a} is selected from azido, -NR₇R₈, OR₁₀, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)cycloalkyl, -(CH₂)_k-R₉, AR₁, AR₂, (1-4C)acyl, -CS(1-4C)alkyl, -C(=W)NR_vR_w [wherein W is O or S,

30 R_v and R_w are independently H, or (1-4C)alkyl], -(C=O)_l-R₆, -COO(1-4C)alkyl, -C=OAR₁, -C=OAR₂, -COOAR₁, S(O)_n(1-4C)alkyl (wherein n = 1 or 2), -S(O)_pAR₁, -S(O)_pAR₂ and -C(=S)O(1-4C)alkyl; wherein any (1-4C)alkyl chain may be optionally substituted by (1-4C)alkyl, cyano, hydroxy or halo; p = 0, 1 or 2;

R4b is selected from HET-3;

R6 is selected from hydrogen, (1-4C)alkoxy, amino, (1-4C)alkylamino and hydroxy(1-4C)alkylamino;

k is 1 or 2;

5 l is 1 or 2;

R7 and R8 are independently selected from H and (1-4C)alkyl, or wherein R7 and R8 taken together with the nitrogen to which they are attached can form a 5-7 membered ring optionally with an additional heteroatom selected from N, O, S(O)_n (wherein n = 1 or 2) in place of 1 carbon atom of the so formed ring; wherein the ring may be optionally substituted
 10 by one or two groups independently selected from (1-4C)alkyl, (1-4C)cycloalkyl, (1-4C)acyl, -COO(1-4C)alkyl, S(O)_n(1-4C)alkyl (wherein n = 1 or 2), AR1, AR2, , -C=OAR1, -C=OAR2, -COOAR1, -CS(1-4C)alkyl, -C(=S)O(1-4C)alkyl, -C(=W)NR_vR_w [wherein W is O or S, R_v and R_w are independently H, or (1-4C)alkyl], -S(O)pAR1 and -S(O)pAR2; wherein any (1-4C)alkyl, (1-4C)cycloalkyl or (1-4C)acyl group may be optionally substituted
 15 (except on a carbon atom adjacent to a heteroatom) by one or two substituents selected from (1-4C)alkyl, cyano, hydroxy, halo, amino, (1-4C)alkylamino and di(1-4C)alkylamino; p = 0, 1 or 2;

R9 is independently selected from R9a to R9d below:


R9a: AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4, AR4a, CY1, CY2;

20 R9b: cyano, carboxy, (1-4C)alkoxycarbonyl, -C(=W)NR_vR_w [wherein W is O or S, R_v and R_w are independently H, or (1-4C)alkyl and wherein R_v and R_w taken together with the amide or thioamide nitrogen to which they are attached can form a 5-7 membered ring optionally with an additional heteroatom selected from N, O, S(O)_n in place of 1 carbon atom of the so formed ring; wherein when said ring is a piperazine ring, the ring may be optionally
 25 substituted on the additional nitrogen by a group selected from (1-4C)alkyl, (1-4C)cycloalkyl, (1-4C)acyl, -COO(1-4C)alkyl, S(O)_n(1-4C)alkyl (wherein n = 1 or 2), -COOAR1, -CS(1-4C)alkyl and -C(=S)O(1-4C)alkyl; wherein any alkyl, acyl or cycloalkyl may itself optionally be substituted by cyano, hydroxy or halo)], ethenyl, 2-(1-4C)alkylethenyl, 2-cyanoethenyl, 2-cyano-2-((1-4C)alkyl)ethenyl, 2-nitroethenyl, 2-nitro-2-
 30 ((1-4C)alkyl)ethenyl, 2-((1-4C)alkylaminocarbonyl)ethenyl, 2-((1-4C)alkoxycarbonyl)ethenyl, 2-(AR1)ethenyl, 2-(AR2)ethenyl, 2-(AR2a)ethenyl;

R9c: (1-6C)alkyl

{optionally substituted by one or more groups (including geminal disubstitution) each


- independently selected from hydroxy, (1-10C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkylcarbonyl, phosphoryl [-O-P(O)(OH)₂], and mono- and di-(1-4C)alkoxy derivatives thereof], phosphiryl [-O-P(OH)₂ and mono- and di-(1-4C)alkoxy derivatives thereof], and amino; and/or optionally substituted by one group
- 5 selected from carboxy, phosphonate [phosphono, -P(O)(OH)₂, and mono- and di-(1-4C)alkoxy derivatives thereof], phosphinate [-P(OH)₂ and mono- and di-(1-4C)alkoxy derivatives thereof], cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-6C)alkanoylamino-, (1-4C)alkoxycarbonylamino-, N-(1-4C)alkyl-
- 10 N-(1-6C)alkanoylamino-, -C(=W)NR_vR_w [wherein W is O or S, R_v and R_w are as hereinbefore defined], (=NOR_v) wherein R_v is as hereinbefore defined, (1-4C)alkylS(O)_pNH, (1-4C)alkylS(O)_p-((1-4C)alkyl)N-, fluoro(1-4C)alkylS(O)_pNH-, fluoro(1-4C)alkylS(O)_p((1-4C)alkyl)N-, (1-4C)alkylS(O)_q-, CY1, CY2, AR1, AR2, AR3, AR1-O-, AR2-O-, AR3-O-, AR1-S(O)_q-, AR2-S(O)_q-, AR3-S(O)_q-, AR1-NH-, AR2-NH-,
- 15 AR3-NH- (p is 1 or 2 and q is 0, 1 or 2), and also AR2a, AR2b, AR3a and AR3b versions of AR2 and AR3 containing groups}; wherein any (1-4C)alkyl present in any substituent on R_{9c} may itself be substituted by one or two groups independently selected from cyano, hydroxy, halo, amino, (1-4C)alkylamino and di(1-4C)alkylamino, provided that such a substituent is not on a carbon adjacent to a heteroatom atom if present;
- 20 R_{9d}: R₁₄C(O)O(1-6C)alkyl- wherein R₁₄ is AR1, AR2, (1-4C)alkylamino, benzyloxy-(1-4C)alkyl or (1-10C)alkyl {optionally substituted as defined for (R_{9c})}; R₁₀ is selected from hydrogen, R_{9c} (as hereinbefore defined), (1-4C)acyl and (1-4C)alkylsulfonyl;
- HET-3 is selected from:
- 25 a) a 5-membered heterocyclic ring containing at least one nitrogen and/or oxygen in which any carbon atom is a C=O, C=N, or C=S group, wherein said ring is of the formula HET3-A to HET3-E below:



HET3-A

HET3-B


HET3-C




HET3-D

HET3-E


b) a carbon-linked 5- or 6-membered heteroaromatic ring containing 1, 2, 3, or 4 heteroatoms independently selected from N, O and S selected from HET3-F to HET3-Y below:




HET3-F




HET3-G




HET3-H




HET3-I




HET3-J















HET3-K



HET3-L












HET3-M

**HET3-N****HET3-O****HET3-P****HET3-Q****HET3-R****HET3-S****HET3-T****HET3-U****HET3-V****HET3-W****HET3-X****HET3-Y**

c) a nitrogen-linked 5- or 6-membered heteroaromatic ring containing 1, 2, 3, or 4 heteroatoms independently selected from N, O and S selected from HET3-Z to HET3-AH

5 below:

**HET3-Z****HET3-AA****HET3-AB****HET3-AC****HET3-AD****HET3-AE****HET3-AF****HET3-AG****HET3-AH**

wherein in HET-3, R_{1a} is a substituent on carbon;

R_{1a} is independently selected from R_{1a1} to R_{1a5} below:

R_{1a1}: AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4, AR4a, CY1, CY2;

R_{1a2}: cyano, carboxy, (1-4C)alkoxycarbonyl, -C(=W)NR_vR_w [wherein W is O or S, R_v and R_w are independently H, or (1-4C)alkyl and wherein R_v and R_w taken together with the

5 amide or thioamide nitrogen to which they are attached can form a 5-7 membered ring

optionally with an additional heteroatom selected from N, O, S(O)_n in place of 1 carbon atom

of the so formed ring; wherein when said ring is a piperazine ring, the ring may be optionally substituted on the additional nitrogen by a group selected from (1-4C)alkyl, (1-4C)cycloalkyl, (1-4C)acyl, -COO(1-4C)alkyl, S(O)_n(1-4C)alkyl (wherein n = 1 or 2), -COOAR1,

10 -CS(1-4C)alkyl) and -C(=S)O(1-4C)alkyl; wherein any (1-4C)alkyl, (1-4C)acyl and

(1-4C)cycloalkyl substituent may itself be substituted by cyano, hydroxy or halo, provided that, such a substituent is not on a carbon adjacent to a nitrogen atom of the piperazine ring],

ethenyl, 2-(1-4C)alkylethenyl, 2-cyanoethenyl, 2-cyano-2-((1-4C)alkyl)ethenyl,

2-nitroethenyl, 2-nitro-2-((1-4C)alkyl)ethenyl, 2-((1-4C)alkylaminocarbonyl)ethenyl,

15 2-((1-4C)alkoxycarbonyl)ethenyl, 2-(AR1)ethenyl, 2-(AR2)ethenyl, 2-(AR2a)ethenyl;

R_{1a3}: (1-10C)alkyl

{optionally substituted by one or more groups (including geminal disubstitution) each

independently selected from hydroxy, (1-10C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy,

(1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkylcarbonyl, phosphoryl [-O-P(O)(OH)₂,

20 and mono- and di-(1-4C)alkoxy derivatives thereof], phosphiryl [-O-P(OH)₂ and mono- and

di-(1-4C)alkoxy derivatives thereof], and amino; and/or optionally substituted by one group

selected from carboxy, phosphonate [phosphono, -P(O)(OH)₂, and mono- and

di-(1-4C)alkoxy derivatives thereof], phosphinate [-P(OH)₂ and mono- and di-(1-4C)alkoxy

derivatives thereof], cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-

25 (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkylamino,

di((1-4C)alkyl)amino, (1-6C)alkanoylamino-, (1-4C)alkoxycarbonylamino-, N-(1-4C)alkyl-

N-(1-6C)alkanoylamino-, -C(=W)NR_vR_w [wherein W is O or S, R_v and R_w are

independently H, or (1-4C)alkyl and wherein R_v and R_w taken together with the amide or

thioamide nitrogen to which they are attached can form a 5-7 membered ring optionally with

30 an additional heteroatom selected from N, O, S(O)_n in place of 1 carbon atom of the so

formed ring; wherein when said ring is a piperazine ring, the ring may be optionally

substituted on the additional nitrogen by a group selected from (1-4C)alkyl, (1-4C)cycloalkyl,

(1-4C)acyl, -COO(1-4C)alkyl, S(O)_n(1-4C)alkyl (wherein n = 1 or 2), -COOAR1,

- CS(1-4C)alkyl and -C(=S)O(1-4C)alkyl], (=NOR_v) wherein R_v is as hereinbefore defined, (1-4C)alkylS(O)_pNH-, (1-4C)alkylS(O)_p-(1-4C)alkylN-, fluoro(1-4C)alkylS(O)_pNH-, fluoro(1-4C)alkylS(O)_p-(1-4C)alkylN-, (1-4C)alkylS(O)_q-, CY1, CY2, AR1, AR2, AR3, AR1-O-, AR2-O-, AR3-O-, AR1-S(O)_q-, AR2-S(O)_q-, AR3-S(O)_q-, AR1-NH-, AR2-NH-,
- 5 AR3-NH- (p is 1 or 2 and q is 0, 1 or 2), and also AR2a, AR2b, AR3a and AR3b versions of AR2 and AR3 containing groups}; wherein any (1-4C)alkyl, (1-4C)acyl and (1-4C)cycloalkyl present in any substituent on R_{1a3} may itself be substituted by one or two groups independently selected from cyano, hydroxy, halo, amino, (1-4C)alkylamino and di(1-4C)alkylamino, provided that such a substituent is not on a carbon adjacent to a
- 10 heteroatom atom if present;
- R_{1a4}: R₁₄C(O)O(1-6C)alkyl- wherein R₁₄ is AR1, AR2, AR2a, AR2b, (1-4C)alkylamino, benzyloxy-(1-4C)alkyl or (1-10C)alkyl {optionally substituted as defined for (R_{1a3})};
- R_{1a5}: F, Cl, hydroxy, mercapto, (1-4C)alkylS(O)_p (p = 0, 1 or 2), -NR₇R₈ (wherein R₇ and R₈ are as hereinbefore defined) or -OR₁₀ (where R₁₀ is as hereinbefore defined);
- 15 m is 0, 1 or 2;
- R₂₁ is selected from hydrogen, methyl [optionally substituted with cyano, trifluoromethyl, -C=WNR_vR_w (where W, R_v and R_w are as hereinbefore defined for R_{1a3}), (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, CY1, CY2, AR1, AR2, AR2a, AR2b (not linked through nitrogen) or
- 20 AR3], (2-10C)alkyl [optionally substituted other than on a carbon attached to the HET-3 ring nitrogen with one or two groups independently selected from the optional substituents defined for R_{1a3}] and R₁₄C(O)O(2-6C)alkyl-, wherein R₁₄ is as defined hereinbefore for R_{1a4} and wherein R₁₄C(O)O group is attached to a carbon other than the carbon attached to the HET-3 ring nitrogen;
- 25 R₂₂ is cyano, -COR₁₂, -COOR₁₂, -CONHR₁₂, -CON(R₁₂)(R₁₃), -SO₂R₁₂ (provided that R₁₂ is not hydrogen), -SO₂NHR₁₂, -SO₂N(R₁₂)(R₁₃) or NO₂, wherein R₁₂ and R₁₃ are as defined hereinbelow;
- R₁₂ and R₁₃ are independently selected from hydrogen, phenyl (optionally substituted with one or more substituents selected from halogen, (1-4C)alkyl and (1-4C)alkyl substituted with
- 30 one, two, three or more halogen atoms) and (1-4C)alkyl (optionally substituted with one, two, three or more halogen atoms), or for any N(R₁₂)(R₁₃) group, R₁₂ and R₁₃ may be taken together with the nitrogen to which they are attached to form a 5-7 membered ring optionally with an additional heteroatom selected from N, O, S(O)_n in place of 1 carbon atom of the so

formed ring; wherein the ring may be optionally substituted by one or two groups independently selected from (1-4C)alkyl (optionally substituted on a carbon not adjacent to the nitrogen by cyano, hydroxy or halo), (1-4C)cycloalkyl, (1-4C)acyl, -COO(1-4C)alkyl, S(O)_n(1-4C)alkyl (wherein n = 1 or 2), AR₁, AR₂, , -C=OAR₁, -C=OAR₂, -COOAR₁,
5 -CS(1-4C)alkyl, -C(=S)O(1-4C)alkyl, -C(=W)NR_vR_w [wherein W is O or S, R_v and R_w are independently H, or (1-4C)alkyl], -S(O)_pAR₁ and -S(O)_pAR₂; wherein any (1-4C)alkyl chain may be optionally substituted by (1-4C)alkyl, cyano, hydroxy or halo; p = 0,1 or 2; AR₁ is an optionally substituted phenyl or optionally substituted naphthyl; AR₂ is an optionally substituted 5- or 6-membered, fully unsaturated (i.e with the maximum
10 degree of unsaturation) monocyclic heteroaryl ring containing up to four heteroatoms independently selected from O, N and S (but not containing any O-O, O-S or S-S bonds), and linked via a ring carbon atom, or a ring nitrogen atom if the ring is not thereby quaternised; AR_{2a} is a partially hydrogenated version of AR₂ (i.e. AR₂ systems retaining some, but not the full, degree of unsaturation), linked via a ring carbon atom or linked via a ring nitrogen
15 atom if the ring is not thereby quaternised; AR_{2b} is a fully hydrogenated version of AR₂ (i.e. AR₂ systems having no unsaturation), linked via a ring carbon atom or linked via a ring nitrogen atom; AR₃ is an optionally substituted 8-, 9- or 10-membered, fully unsaturated (i.e with the maximum degree of unsaturation) bicyclic heteroaryl ring containing up to four heteroatoms
20 independently selected from O, N and S (but not containing any O-O, O-S or S-S bonds), and linked via a ring carbon atom in either of the rings comprising the bicyclic system; AR_{3a} is a partially hydrogenated version of AR₃ (i.e. AR₃ systems retaining some, but not the full, degree of unsaturation), linked via a ring carbon atom, or linked via a ring nitrogen atom if the ring is not thereby quaternised, in either of the rings comprising the bicyclic
25 system; AR_{3b} is a fully hydrogenated version of AR₃ (i.e. AR₃ systems having no unsaturation), linked via a ring carbon atom, or linked via a ring nitrogen atom, in either of the rings comprising the bicyclic system; AR₄ is an optionally substituted 13- or 14-membered, fully unsaturated (i.e with the
30 maximum degree of unsaturation) tricyclic heteroaryl ring containing up to four heteroatoms independently selected from O, N and S (but not containing any O-O, O-S or S-S bonds), and linked via a ring carbon atom in any of the rings comprising the tricyclic system; AR_{4a} is a partially hydrogenated version of AR₄ (i.e. AR₄ systems retaining some, but not

the full, degree of unsaturation), linked via a ring carbon atom, or linked via a ring nitrogen atom if the ring is not thereby quaternised, in any of the rings comprising the tricyclic system;

CY1 is an optionally substituted cyclobutyl, cyclopentyl or cyclohexyl ring;

CY2 is an optionally substituted cyclopentenyl or cyclohexenyl ring;

5 wherein; optional substituents on AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4, AR4a,

CY1 and CY2 are (on an available carbon atom) up to three substituents independently

selected from (1-4C)alkyl {optionally substituted by substituents selected independently from hydroxy, trifluoromethyl, (1-4C)alkyl S(O)_q- (q is 0, 1 or 2), (1-4C)alkoxy,

(1-4C)alkoxycarbonyl, cyano, nitro, (1-4C)alkanoylamino, -CONR_vR_w or -NR_vR_w},

10 trifluoromethyl, hydroxy, halo, nitro, cyano, thiol, (1-4C)alkoxy, (1-4C)alkanoyloxy,

dimethylaminomethyleneaminocarbonyl, di(N-(1-4C)alkyl)aminomethylimino, carboxy,

(1-4C)alkoxycarbonyl, (1-4C)alkanoyl, (1-4C)alkylSO₂amino, (2-4C)alkenyl {optionally substituted by carboxy or (1-4C)alkoxycarbonyl}, (2-4C)alkynyl, (1-4C)alkanoylamino, oxo (=O), thioxo (=S), (1-4C)alkanoylamino {the (1-4C)alkanoyl group being optionally

15 substituted by hydroxy}, (1-4C)alkyl S(O)_q- (q is 0, 1 or 2) {the (1-4C)alkyl group being

optionally substituted by one or more groups independently selected from cyano, hydroxy and (1-4C)alkoxy}, -CONR_vR_w or -NR_vR_w [wherein R_v is hydrogen or (1-4C)alkyl; R_w is hydrogen or (1-4C)alkyl];

and further optional substituents on AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4,

20 AR4a, CY1 and CY2 (on an available carbon atom), and also on alkyl groups (unless

indicated otherwise) are up to three substituents independently selected from

trifluoromethoxy, benzoylamino, benzoyl, phenyl {optionally substituted by up to three substituents independently selected from halo, (1-4C)alkoxy or cyano}, furan, pyrrole,

pyrazole, imidazole, triazole, pyrimidine, pyridazine, pyridine, isoxazole, oxazole, isothiazole,

25 thiazole, thiophene, hydroxyimino(1-4C)alkyl, (1-4C)alkoxyimino(1-4C)alkyl,

halo-(1-4C)alkyl, (1-4C)alkanesulfonamido, -SO₂NR_vR_w [wherein R_v is hydrogen or (1-4C)alkyl; R_w is hydrogen or (1-4C)alkyl]; and

optional substituents on AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4 and AR4a are (on an available nitrogen atom, where such substitution does not result in quaternization)

30 (1-4C)alkyl, (1-4C)alkanoyl {wherein the (1-4C)alkyl and (1-4C)alkanoyl groups are

optionally substituted by (preferably one) substituents independently selected from cyano, hydroxy, nitro, trifluoromethyl, (1-4C)alkyl S(O)_q- (q is 0, 1 or 2), (1-4C)alkoxy,

(1-4C)alkoxycarbonyl, (1-4C)alkanoylamino, -CONR_vR_w or -NR_vR_w [wherein R_v is hydrogen or (1-4C)alkyl; R_w is hydrogen or (1-4C)alkyl]}, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxycarbonyl or oxo (to form an N-oxide).

5 In this specification the term 'alkyl' includes straight chained and branched structures. For example, (1-4C)alkyl includes propyl and isopropyl. However, references to individual alkyl groups such as "propyl" are specific for the straight chained version only, and references to individual branched chain alkyl groups such as "isopropyl" are specific for the branched chain version only. In this specification, the terms 'alkenyl' and 'cycloalkenyl' include all positional and geometrical isomers. In this specification, the term 'aryl' is an unsubstituted carbocyclic aromatic group, in particular phenyl, 1- and 2-naphthyl.

For the avoidance of doubt, reference to a carbon atom in HET1 or HET2 being substituted by an oxo or thioxo group means replacement of a CH₂ by C=O or C=S respectively.

15 There follow particular and suitable values for certain substituents and groups referred to in this specification. These values may be used where appropriate with any of the definitions and embodiments disclosed hereinbefore, or hereinafter. For the avoidance of doubt each stated species represents a particular and independent aspect of this invention.

Examples of (1-4C)alkyl and (1-5C)alkyl include methyl, ethyl, propyl, isopropyl and 20 t-butyl; examples of (1-6C)alkyl include methyl, ethyl, propyl, isopropyl, t-butyl, pentyl and hexyl; examples of (1-10C)alkyl include methyl, ethyl, propyl, isopropyl, pentyl, hexyl, heptyl, octyl and nonyl; examples of (1-4C)alkanoylamino-(1-4C)alkyl include formamidomethyl, acetamidomethyl and acetamidoethyl; examples of hydroxy(1-4C)alkyl and hydroxy(1-6C)alkyl include hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl and 25 3-hydroxypropyl; examples of (1-4C)alkoxycarbonyl include methoxycarbonyl, ethoxycarbonyl and propoxycarbonyl; examples of 2-((1-4C)alkoxycarbonyl)ethenyl include 2-(methoxycarbonyl)ethenyl and 2-(ethoxycarbonyl)ethenyl; examples of 2-cyano-2-((1-4C)alkyl)ethenyl include 2-cyano-2-methylethenyl and 2-cyano-2-ethylethenyl; examples of 2-nitro-2-((1-4C)alkyl)ethenyl include 2-nitro-2-methylethenyl and 2-nitro-2-30 ethylethenyl; examples of 2-((1-4C)alkylaminocarbonyl)ethenyl include 2-(methylaminocarbonyl)ethenyl and 2-(ethylaminocarbonyl)ethenyl; examples of (2-4C)alkenyl include allyl and vinyl; examples of (2-4C)alkynyl include ethynyl and 2-propynyl; examples of (1-4C)acyl include formyl, acetyl and propionyl; examples of

(2-4C)acyl include acetyl and propionyl; examples of (1-4C)alkoxy include methoxy, ethoxy and propoxy; examples of (1-6C)alkoxy and (1-10C)alkoxy include methoxy, ethoxy, propoxy and pentoxy; examples of (1-4C)alkylthio include methylthio and ethylthio; examples of (1-4C)alkylamino include methylamino, ethylamino and propylamino; examples of di-((1-4C)alkyl)amino include dimethylamino, N-ethyl-N-methylamino, diethylamino, N-methyl-N-propylamino and dipropylamino; examples of halo groups include fluoro, chloro and bromo; examples of (1-4C)alkylsulfonyl include methylsulfonyl and ethylsulfonyl; examples of (1-4C)alkoxy-(1-4C)alkoxy and (1-6C)alkoxy-(1-6C)alkoxy include methoxymethoxy, 2-methoxyethoxy, 2-ethoxyethoxy and 3-methoxypropoxy; examples of (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxy include 2-(methoxymethoxy)ethoxy, 2-(2-methoxyethoxy)ethoxy; 3-(2-methoxyethoxy)propoxy and 2-(2-ethoxyethoxy)ethoxy; examples of (1-4C)alkylS(O)₂amino include methylsulfonylamino and ethylsulfonylamino; examples of (1-4C)alkanoylamino and (1-6C)alkanoylamino include formamido, acetamido and propionylamino; examples of (1-4C)alkoxycarbonylamino include methoxycarbonylamino and ethoxycarbonylamino; examples of N-(1-4C)alkyl-N-(1-6C)alkanoylamino include N-methylacetamido, N-ethylacetamido and N-methylpropionamido; examples of (1-4C)alkylS(O)_pNH- wherein p is 1 or 2 include methylsulfinylamino, methylsulfonylamino, ethylsulfinylamino and ethylsulfonylamino; examples of (1-4C)alkylS(O)_p((1-4C)alkyl)N- wherein p is 1 or 2 include methylsulfinylmethylamino, methylsulfonylmethylamino, 2-(ethylsulfinyl)ethylamino and 2-(ethylsulfonyl)ethylamino; examples of fluoro(1-4C)alkylS(O)_pNH- wherein p is 1 or 2 include trifluoromethylsulfinylamino and trifluoromethylsulfonylamino; examples of fluoro(1-4C)alkylS(O)_p((1-4C)alkyl)NH- wherein p is 1 or 2 include trifluoromethylsulfinylmethylamino and trifluoromethylsulfonylmethylamino examples of (1-4C)alkoxy(hydroxy)phosphoryl include methoxy(hydroxy)phosphoryl and ethoxy(hydroxy)phosphoryl; examples of di-(1-4C)alkoxyphosphoryl include dimethoxyphosphoryl, di-ethoxyphosphoryl and ethoxy(methoxy)phosphoryl; examples of (1-4C)alkylS(O)_q- wherein q is 0, 1 or 2 include methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl and ethylsulfonyl; examples of phenylS(O)_q and naphthylS(O)_q- wherein q is 0, 1 or 2 are phenylthio, phenylsulfinyl, phenylsulfonyl and naphthylthio, naphthylsulfinyl and naphthylsulfonyl respectively; examples of benzyloxy-(1-4C)alkyl include benzyloxymethyl and benzyloxyethyl; examples of a (3-4C)alkylene chain are trimethylene or tetramethylene; examples of (1-6C)alkoxy-(1-6C)alkyl include

- methoxymethyl, ethoxymethyl and 2-methoxyethyl; examples of **hydroxy-(2-6C)alkoxy** include 2-hydroxyethoxy and 3-hydroxypropoxy; examples of **(1-4C)alkylamino-(2-6C)alkoxy** include 2-methylaminoethoxy and 2-ethylaminoethoxy; examples of **di-(1-4C)alkylamino-(2-6C)alkoxy** include 2-dimethylaminoethoxy and
- 5 2-diethylaminoethoxy;
- examples of **phenyl(1-4C)alkyl** include benzyl and phenethyl; examples of **(1-4C)alkylcarbamoyl** include methylcarbamoyl and ethylcarbamoyl; examples of **di((1-4C)alkyl)carbamoyl** include di(methyl)carbamoyl and di(ethyl)carbamoyl; examples of **hydroxyimino(1-4C)alkyl** include hydroxyiminomethyl, 2-(hydroxyimino)ethyl and
- 10 1-(hydroxyimino)ethyl; examples of **(1-4C)alkoxyimino-(1-4C)alkyl** include methoxyiminomethyl, ethoxyiminomethyl, 1-(methoxyimino)ethyl and 2-(methoxyimino)ethyl; examples of **halo(1-4C)alkyl** include, halomethyl, 1-haloethyl, 2-haloethyl, and 3-halopropyl; examples of **nitro(1-4C)alkyl** include nitromethyl, 1-nitroethyl, 2-nitroethyl and 3-nitropropyl; examples of **amino(1-4C)alkyl** include
- 15 aminomethyl, 1-aminoethyl, 2-aminoethyl and 3-aminopropyl; examples of **cyano(1-4C)alkyl** include cyanomethyl, 1-cyanoethyl, 2-cyanoethyl and 3-cyanopropyl; examples of **(1-4C)alkanesulfonamido** include methanesulfonamido and ethanesulfonamido; examples of **(1-4C)alkylaminosulfonyl** include methylaminosulfonyl and ethylaminosulfonyl; examples of **di-(1-4C)alkylaminosulfonyl** include dimethylaminosulfonyl, diethylaminosulfonyl and
- 20 N-methyl-N-ethylaminosulfonyl; examples of **(1-4C)alkanesulfonyloxy** include methylsulfonyloxy, ethylsulfonyloxy and propylsulfonyloxy; examples of **(1-4C)alkanoyloxy** include acetoxy; examples of **(1-4C)alkylaminocarbonyl** include methylaminocarbonyl and ethylaminocarbonyl; examples of **di((1-4C)alkyl)aminocarbonyl** include dimethylaminocarbonyl and diethylaminocarbonyl; examples of **(3-8C)cycloalkyl** include
- 25 cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; examples of **(4-7C)cycloalkyl** include cyclobutyl, cyclopentyl and cyclohexyl; examples of **di(N-(1-4C)alkyl)aminomethylimino** include dimethylaminomethylimino and diethylaminomethylimino.

Particular values for AR2 include, for example, for those AR2 containing one heteroatom, furan, pyrrole, thiophene; for those AR2 containing one to four N atoms,

30 pyrazole, imidazole, pyridine, pyrimidine, pyrazine, pyridazine, 1,2,3- & 1,2,4-triazole and tetrazole; for those AR2 containing one N and one O atom, oxazole, isoxazole and oxazine; for those AR2 containing one N and one S atom, thiazole and isothiazole; for those AR2 containing two N atoms and one S atom, 1,2,4- and 1,3,4-thiadiazole.

Particular examples of AR2a include, for example, dihydropyrrole (especially 2,5-dihydropyrrol-4-yl) and tetrahydropyridine (especially 1,2,5,6-tetrahydropyrid-4-yl).

Particular examples of AR2b include, for example, tetrahydrofuran, pyrrolidine, morpholine (preferably morpholino), thiomorpholine (preferably thiomorpholino), piperazine (preferably piperazino), imidazoline and piperidine, 1,3-dioxolan-4-yl, 1,3-dioxan-4-yl, 1,3-dioxan-5-yl and 1,4-dioxan-2-yl.

Particular values for AR3 include, for example, bicyclic benzo-fused systems containing a 5- or 6-membered heteroaryl ring containing one nitrogen atom and optionally 1-3 further heteroatoms chosen from oxygen, sulfur and nitrogen. Specific examples of such ring systems include, for example, indole, benzofuran, benzothiophene, benzimidazole, benzothiazole, benzisothiazole, benzoxazole, benzisoxazole, quinoline, quinoxaline, quinazoline, phthalazine and cinnoline.

Other particular examples of AR3 include 5/5-, 5/6 and 6/6 bicyclic ring systems containing heteroatoms in both of the rings. Specific examples of such ring systems include, for example, purine and naphthyridine.

Further particular examples of AR3 include bicyclic heteroaryl ring systems with at least one bridgehead nitrogen and optionally a further 1-3 heteroatoms chosen from oxygen, sulfur and nitrogen. Specific examples of such ring systems include, for example, 3H-pyrrolo[1,2-a]pyrrole, pyrrolo[2,1-b]thiazole, 1H-imidazo[1,2-a]pyrrole, 1H-imidazo[1,2-a]imidazole, 1H,3H-pyrrolo[1,2-c]oxazole, 1H-imidazo[1,5-a]pyrrole, pyrrolo[1,2-b]isoxazole, imidazo[5,1-b]thiazole, imidazo[2,1-b]thiazole, indolizine, imidazo[1,2-a]pyridine, imidazo[1,5-a]pyridine, pyrazolo[1,5-a]pyridine, pyrrolo[1,2-b]pyridazine, pyrrolo[1,2-c]pyrimidine, pyrrolo[1,2-a]pyrazine, pyrrolo[1,2-a]pyrimidine, pyrido[2,1-c]-s-triazole, s-triazole[1,5-a]pyridine, imidazo[1,2-c]pyrimidine, imidazo[1,2-a]pyrazine, imidazo[1,2-a]pyrimidine, imidazo[1,5-a]pyrazine, imidazo[1,5-a]pyrimidine, imidazo[1,2-b]-pyridazine, s-triazolo[4,3-a]pyrimidine, imidazo[5,1-b]oxazole and imidazo[2,1-b]oxazole. Other specific examples of such ring systems include, for example, [1H]-pyrrolo[2,1-c]oxazine, [3H]-oxazolo[3,4-a]pyridine, [6H]-pyrrolo[2,1-c]oxazine and pyrido[2,1-c][1,4]oxazine. Other specific examples of 5/5- bicyclic ring systems are imidazooxazole or imidazothiazole, in particular imidazo[5,1-b]thiazole, imidazo[2,1-b]thiazole, imidazo[5,1-b]oxazole or imidazo[2,1-b]oxazole.

Particular examples of AR3a and AR3b include, for example, indoline,

1,3,4,6,9,9a-hexahydropyrido[2,1c][1,4]oxazin-8-yl, 1,2,3,5,8,8a-hexahydroimidazo[1,5a]pyridin-7-yl, 1,5,8,8a-tetrahydrooxazolo[3,4a]pyridin-7-yl, 1,5,6,7,8,8a-hexahydrooxazolo[3,4a]pyridin-7-yl, (7aS)[3H,5H]-1,7a-dihydropyrrolo[1,2c]oxazol-6-yl, (7aS)[5H]-1,2,3,7a-tetrahydropyrrolo[1,2c]imidazol-6-yl, 5 (7aR)[3H,5H]-1,7a-dihydropyrrolo[1,2c]oxazol-6-yl, [3H,5H]-pyrrolo[1,2-c]oxazol-6-yl, [5H]-2,3-dihydropyrrolo[1,2-c]imidazol-6-yl, [3H,5H]-pyrrolo[1,2-c]thiazol-6-yl, [3H,5H]-1,7a-dihydropyrrolo[1,2-c]thiazol-6-yl, [5H]-pyrrolo[1,2-c]imidazol-6-yl, [1H]-3,4,8,8a-tetrahydropyrrolo[2,1-c]oxazin-7-yl, [3H]-1,5,8,8a-tetrahydrooxazolo[3,4-a]pyrid-7-yl, [3H]-5,8-dihydrooxazolo[3,4-a]pyrid-7-yl and 5,8-dihydroimidazo-10 [1,5-a]pyrid-7-yl.

Particular values for AR4 include, for example, pyrrolo[a]quinoline, 2,3-pyrroloisoquinoline, pyrrolo[a]isoquinoline, 1H-pyrrolo[1,2-a]benzimidazole, 9H-imidazo[1,2-a]indole, 5H-imidazo[2,1-a]isoindole, 1H-imidazo[3,4-a]indole, imidazo[1,2-a]quinoline, imidazo[2,1-a]isoquinoline, imidazo[1,5-a]quinoline and 15 imidazo[5,1-a]isoquinoline.

The nomenclature used is that found in, for example, "Heterocyclic Compounds (Systems with bridgehead nitrogen), W.L.Mosby (Interscience Publishers Inc., New York), 1961, Parts 1 and 2.

Where optional substituents are listed such substitution is preferably not geminal 20 disubstitution unless stated otherwise. If not stated elsewhere, suitable optional substituents for a particular group are those as stated for similar groups herein.

Preferable optional substituents on Ar2b as 1,3-dioxolan-4-yl, 1,3-dioxan-4-yl, 1,3-dioxan-5-yl or 1,4-dioxan-2-yl are mono- or disubstitution by substituents independently selected from (1-4C)alkyl (including geminal disubstitution), (1-4C)alkoxy, (1-4C)alkylthio, 25 acetamido, (1-4C)alkanoyl, cyano, trifluoromethyl and phenyl].

Preferable optional substituents on CY1 & CY2 are mono- or disubstitution by substituents independently selected from (1-4C)alkyl (including geminal disubstitution), hydroxy, (1-4C)alkoxy, (1-4C)alkylthio, acetamido, (1-4C)alkanoyl, cyano, and trifluoromethyl.

Suitable pharmaceutically-acceptable salts include acid addition salts such as 30 methanesulfonate, fumarate, hydrochloride, citrate, maleate, tartrate and (less preferably) hydrobromide. Also suitable are salts formed with phosphoric and sulfuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example

triethylamine, morpholine, N-methylpiperidine, N-ethylpiperidine, procaine, dibenzylamine, N,N-dibenzylethylamine, tris-(2-hydroxyethyl)amine, N-methyl d-glucamine and amino acids such as lysine. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations or anions. A preferred pharmaceutically-

5 acceptable salt is the sodium salt.

However, to facilitate isolation of the salt during preparation, salts which are less soluble in the chosen solvent may be preferred whether pharmaceutically-acceptable or not.

The compounds of the invention may be administered in the form of a pro-drug which is broken down in the human or animal body to give a compound of the invention. A prodrug
10 may be used to alter or improve the physical and/or pharmacokinetic profile of the parent compound and can be formed when the parent compound contains a suitable group or substituent which can be derivatised to form a prodrug. Examples of pro-drugs include in-vivo hydrolysable esters of a compound of the invention or a pharmaceutically-acceptable salt thereof.

15 Various forms of prodrugs are known in the art, for examples see:


- a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, *et al.* (Academic Press, 1985);
- b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs", by H. Bundgaard p. 113-191
20 (1991);
- c) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992);
- d) H. Bundgaard, *et al.*, Journal of Pharmaceutical Sciences, 77, 285 (1988); and
- e) N. Kakeya, *et al.*, Chem Pharm Bull, 32, 692 (1984).

An in-vivo hydrolysable ester of a compound of the invention or a pharmaceutically-
25 acceptable salt thereof containing a carboxy or hydroxy group is, for example, a pharmaceutically-acceptable ester which is hydrolysed in the human or animal body to produce the parent alcohol.

Suitable pharmaceutically-acceptable esters for carboxy include (1-6C)alkoxymethyl esters for example methoxymethyl, (1-6C)alkanoyloxymethyl esters for example
30 pivaloyloxymethyl, phthalidyl esters, (3-8C)cycloalkoxycarbonyloxy(1-6C)alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolan-2-onylmethyl esters for example 5-methyl-1,3-dioxolan-2-ylmethyl; and (1-6C)alkoxycarbonyloxyethyl esters for example


1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.

Suitable pro-drugs for pyridine derivatives include acyloxymethyl pyridinium salts eg halides; for example a pro-drug such as:




An in-vivo hydrolysable ester of a compound of the invention or a pharmaceutically-acceptable salt thereof containing a hydroxy group or groups includes inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and α -acyloxyalkyl ethers and related compounds which as a result of the in-vivo hydrolysis of the ester breakdown to give the parent hydroxy group/s. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxymethoxy. A selection of in-vivo hydrolysable ester forming groups for hydroxy include (1-10C)alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, (1-10C)alkoxycarbonyl (to give alkyl carbonate esters), di-(1-4C)alkylcarbamoyl and N-(di-(1-4C)alkylaminoethyl)-N-(1-4C)alkylcarbamoyl (to give carbamates), di-(1-4C)alkylaminoacetyl, carboxy(2-5C)alkylcarbonyl and carboxyacetyl. Examples of ring substituents on phenylacetyl and benzoyl include chloromethyl or aminomethyl, (1-4C)alkylaminomethyl and di-((1-4C)alkyl)aminomethyl, and morpholino or piperazino linked from a ring nitrogen atom via a methylene linking group to the 3- or 4-position of the benzoyl ring. Other interesting in-vivo hydrolysable esters include, for example, $R^A C(O)O(1-6C)alkyl-CO-$ (wherein R^A is for example, optionally substituted benzyloxy-(1-4C)alkyl, or optionally substituted phenyl; suitable substituents on a phenyl group in such esters include, for example, 4-(1-4C)piperazino-(1-4C)alkyl, piperazino-(1-4C)alkyl and morpholino-(1-4C)alkyl.


Suitable in-vivo hydrolysable esters of a compound of the formula (I) are described as follows. For example, a 1,2-diol may be cyclised to form a cyclic ester of formula (PD1) or a pyrophosphate of formula (PD2), and a 1,3-diol may be cyclised to form a cyclic ester of the formula (PD3):



(PD1)




(PD2)



(PD3)

Esters of compounds of formula (I) wherein the HO- function/s in (PD1), (PD2) and (PD3) are protected by (1-4C)alkyl, phenyl or benzyl are useful intermediates for the
5 preparation of such pro-drugs.

Further in-vivo hydrolysable esters include phosphoramidic esters, and also compounds of invention in which any free hydroxy group independently forms a phosphoryl (npd is 1) or phosphiryl (npd is 0) ester of the formula (PD4) :




(PD4)

For the avoidance of doubt, phosphono is $-P(O)(OH)_2$; (1-4C)alkoxy(hydroxy)-phosphoryl is a mono-(1-4C)alkoxy derivative of $-O-P(O)(OH)_2$; and di-(1-4C)alkoxyphosphoryl is a di-(1-4C)alkoxy derivative of $-O-P(O)(OH)_2$.

Useful intermediates for the preparation of such esters include compounds containing a group/s of formula (PD4) in which either or both of the -OH groups in (PD1) is independently protected by (1-4C)alkyl (such compounds also being interesting compounds in their own right), phenyl or phenyl-(1-4C)alkyl (such phenyl groups being optionally substituted by 1 or 2 groups independently selected from (1-4C)alkyl, nitro, halo and
20 (1-4C)alkoxy).

Thus, prodrugs containing groups such as (PD1), (PD2), (PD3) and (PD4) may be prepared by reaction of a compound of invention containing suitable hydroxy group/s with a suitably protected phosphorylating agent (for example, containing a chloro or dialkylamino leaving group), followed by oxidation (if necessary) and deprotection.


Other suitable prodrugs include phosphonooxymethyl ethers and their salts, for example a prodrug of R-OH such as:



When a compound of invention contains a number of free hydroxy group, those groups not being converted into a prodrug functionality may be protected (for example, using a t-butyl-dimethylsilyl group), and later deprotected. Also, enzymatic methods may be used to selectively phosphorylate or dephosphorylate alcohol functionalities.

Where pharmaceutically-acceptable salts of an in-vivo hydrolysable ester may be formed this is achieved by conventional techniques. Thus, for example, compounds containing a group of formula (PD1), (PD2), (PD3) and/or (PD4) may ionise (partially or fully) to form salts with an appropriate number of counter-ions. Thus, by way of example, if an in-vivo hydrolysable ester prodrug of a compound of invention contains two (PD4) groups, there are four HO-P- functionalities present in the overall molecule, each of which may form an appropriate salt (i.e. the overall molecule may form, for example, a mono-, di-, tri- or tetra-sodium salt).

The compounds of the present invention have a chiral centre at the C-5 positions of the oxazolidinone ring. The pharmaceutically active diastereomer is of the formula (IA):



(IA)

which is generally the (5R) configuration, depending on the nature of R_{1b} and C.

The present invention includes pure diastereomers or mixtures of diastereomers, for example a racemic mixture. If a mixture of enantiomers is used, a larger amount (depending upon the ratio of the enantiomers) will be required to achieve the same effect as the same weight of the pharmaceutically active enantiomer.

Furthermore, some compounds of the invention may have other chiral centres, for example on substituents on group C. It is to be understood that the invention encompasses all

such optical and diastereoisomers, and racemic mixtures, that possess antibacterial activity. It is well known in the art how to prepare optically-active forms (for example by resolution of the racemic form by recrystallisation techniques, by chiral synthesis, by enzymatic resolution, by biotransformation or by chromatographic separation) and how to determine antibacterial activity as described hereinafter.

The invention relates to all tautomeric forms of the compounds of the invention that possess antibacterial activity.

It is also to be understood that certain compounds of the invention can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess antibacterial activity.

It is also to be understood that certain compounds of the invention may exhibit polymorphism, and that the invention encompasses all such forms which possess antibacterial activity.

As stated before, we have discovered a range of compounds that have good activity against a broad range of Gram-positive pathogens including organisms known to be resistant to most commonly used antibiotics, together with activity against fastidious Gram negative pathogens such as *H.influenzae*, *M.catarrhalis*, *Mycoplasma* and *Chlamydia* strains. The following compounds possess preferred pharmaceutical and/or physical and/or pharmacokinetic properties.

In one embodiment of the invention are provided compounds of formula (I), in an alternative embodiment are provided pharmaceutically-acceptable salts of compounds of formula (I), in a further alternative embodiment are provided in-vivo hydrolysable esters of compounds of formula (I), and in a further alternative embodiment are provided pharmaceutically-acceptable salts of in-vivo hydrolysable esters of compounds of formula (I).

In one aspect, an in-vivo hydrolysable ester of a compound of the formula (I) is a phosphoryl ester (as defined by formula (PD4) with npd as 1).

Compounds of the formula (I), or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, wherein C is selected from group D or group E represent separate and independent aspects of the invention.

Particularly preferred compounds of the invention comprise a compound of the invention, or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, wherein the substituents R_{1a} , R_{1b} , R_{2a} , R_{2b} , R_{3a} , R_{6a} and R_{6b} and other substituents

mentioned above have values disclosed hereinbefore, or any of the following values (which may be used where appropriate with any of the definitions and embodiments disclosed hereinbefore or hereinafter):

In one embodiment are provided compounds of the formula (I) or pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof wherein group C is group D.

In another embodiment are provided compounds of the formula (I) or pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof wherein group C is group E.

In one aspect R_{2a} and R_{6a} are hydrogen.

10 In one aspect one R_{2b} and R_{6b} is fluoro and the other is hydrogen. In another aspect both one R_{2b} and R_{6b} are fluoro. In a further aspect R_{2b} is fluoro and R_{6b} is selected from Cl, CF_3 , Me, Et, OMe and SMe.

In one aspect one of R_{2b} and R_{6b} is chloro and other hydrogen.

In another aspect one of R_{2b} and R_{6b} is CF_3 and the other hydrogen.

15 In another aspect one of R_{2b} and R_{6b} is Me and the other hydrogen.







In another aspect one of R_{2b} and R_{6b} is Et and the other hydrogen.

In another aspect one of R_{2b} and R_{6b} is OMe and the other hydrogen.

In another aspect one of R_{2b} and R_{6b} is SMe and the other hydrogen.

20 In one aspect R_{3a} is selected from H, (1-4C)alkyl, cyano, Br, F, Cl, OH, (1-4C)alkoxy, -S(1-4C)alkyl, amino, nitro and -CHO. In a further aspect R_{3a} is selected from H, Cl, Br, F, Me, Et, OMe and SMe.

In one embodiment R_{1b} is HET1 wherein HET1 is selected from the structures (Za) to (Zf) below:



wherein u and v are independently 0 or 1 and RT is as defined in any of the embodiments or aspects defined hereinbefore or hereinafter.

- 5 In one embodiment R1b is HET1 wherein HET1 is selected from 1,2,3-triazole (especially 1,2,3-triazol-1-yl (Zd)), 1,2,4-triazole (especially 1,2,4-triazol-1-yl (Zc)) and tetrazole (preferably tetrazol-2-yl (Zf)) and wherein u and v are independently 0 or 1 and RT is as defined in any of the embodiments or aspects defined hereinbefore or hereinafter.

- 10 In another embodiment R1b is HET1 wherein HET1 is selected from 1,2,3-triazol-1-yl (Zd) and tetrazol-2-yl (Zf) and wherein u and v are independently 0 or 1 and RT is as defined in any of the embodiments or aspects defined hereinbefore or hereinafter.

In another embodiment R1b is HET1 wherein HET1 is 1,2,3-triazol-1-yl (Zd) and wherein u and v are independently 0 or 1 and RT is as defined in any of the embodiments or aspects defined hereinbefore or hereinafter.

- 15 In one embodiment R1b is HET2 wherein HET2 is a di-hydro version of pyrimidine, pyridazine, pyrazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine and pyridine and wherein RT is as defined in any of the embodiments or aspects defined hereinbefore or hereinafter.

- In another embodiment R1b is HET2 wherein HET2 is selected from pyrimidone, pyridazinone, pyrazinone, 1,2,3-triazinone, 1,2,4-triazinone, 1,3,5-triazinone and pyridone
20 and wherein RT is as defined in any of the embodiments or aspects defined hereinbefore or hereinafter.

In another embodiment R1b is HET2 wherein HET2 is selected from thiopyrimidone, thiopyridazinone, thiopyrazinone, thio-1,2,3-triazinone, thio-1,2,4-triazinone, thio-1,3,5-

triazinone and thiopyridone and wherein RT is as defined in any of the embodiments or aspects defined hereinbefore or hereinafter.

In one aspect RT is preferably selected from a substituent from the groups RTa1 to RTb2, wherein:

- 5 (RTa1) hydrogen, halogen, (1-4C)alkoxy, (2-4C)alkenyloxy, (2-4C)alkenyl,
... (2-4C)alkynyl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, (1-4C)alkylthio, amino, azido, cyano
and nitro;
(RTa2) (1-4C)alkylamino, di-(1-4C)alkylamino and (2-4C)alkenylamino;
(RTb1) a (1-4C)alkyl group which is optionally substituted by one substituent selected
10 from hydroxy, (1-4C)alkoxy, (1-4C)alkylthio, cyano and azido;
(RTb2) a (1-4C)alkyl group which is optionally substituted by one substituent selected
from (2-4C)alkenyloxy, (3-6C)cycloalkyl and (3-6C)cycloalkenyl;
and wherein at each occurrence of an RT substituent containing an alkyl, alkenyl, alkynyl,
cycloalkyl or cycloalkenyl moiety in (RTa1) or (RTa2), or (RTb1) or (RTb2) each such
15 moiety is optionally substituted on an available carbon atom with one, two, three or more
substituents independently selected from F, Cl, Br, OH and CN.

In another aspect RT is preferably selected from a substituent from the groups RTa1 and RTb1, wherein:

- (RTa1) hydrogen, halogen, (1-4C)alkoxy, (2-4C)alkenyloxy, (2-4C)alkenyl,
20 (2-4C)alkynyl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, (1-4C)alkylthio, amino, azido, cyano,
and nitro;
(RTb1) a (1-4C)alkyl group which is optionally substituted by one substituent selected
from hydroxy, (1-4C)alkoxy, (1-4C)alkylthio, cyano and azido;
and wherein at each occurrence of an RT substituent containing an alkyl, alkenyl, alkynyl,
25 cycloalkyl or cycloalkenyl moiety in (RTa1) or (RTb1) each such moiety is optionally
substituted on an available carbon atom with one, two, three or more substituents
independently selected from F, Cl, Br, and CN.

In a further aspect RT is most preferably

- (a) hydrogen; or
30 (b) halogen, in particular fluorine, chlorine, or bromine; or
(c) cyano; or
(d) (1-4C)alkyl, in particular methyl; or

- (e) monosubstituted (1-4C)alkyl, in particular fluoromethyl, chloromethyl, bromomethyl, cyanomethyl, azidomethyl, hydroxymethyl; or
- (f) disubstituted (1-4C)alkyl, for example difluoromethyl, or
- (g) trisubstituted (1-4C)alkyl, for example trifluoromethyl.

5 In one aspect R4 is selected from R4a. In another aspect R4 is selected from R4b.

..... In one aspect R4a is selected from (1-4C)alkyl, (1-4C)cycloalkyl, AR1, AR2, (1-4C)acyl, -CS(1-4C)alkyl, -C(=W)NRvRw [wherein W is O or S, Rv and Rw are independently H, or (1-4C)alkyl], -COO(1-4C)alkyl, -C=OAR1, -C=OAR2, -COOAR1, S(O)n(1-4C)alkyl (wherein n = 1 or 2), -S(O)pAR1, -S(O)pAR2 and -C(=S)O(1-4C)alkyl;

10 wherein any (1-4C)alkyl chain may be optionally substituted by (1-4C)alkyl, cyano, hydroxy or halo; p = 0, 1 or 2).

In a further aspect R4a is selected from azido, -NR7R8, OR10(1-4C)alkoxy, -(CH2)m-R9 and -(C=O)l-R6,

In one aspect HET-3 is selected from HET3-A, HET3-B, HET3-C, HET3-D and
15 HET3-E.

In another aspect HET-3 is selected from HET3-F, HET3-G, HET3-H and HET3-I.

In another aspect HET-3 is selected from HET3-J, HET3-K, HET3-L, HET3-M, HET3-N, HET3-O, HET3-P, HET3-Q, HET3-R and HET3-S.

In a further aspect HET-3 is selected from HET3-J, HET3-L, HET3-M, HET3-N,
20 HET3-P, HET3-Q, HET3-R and HET3-S.

In a further aspect HET-3 is selected from HET3-L and HET3-M.

In a further aspect HET-3 is selected from HET3-P and HET3-Q.

In a further aspect HET-3 is selected from HET3-T, HET3-U, HET3-V, HET3-W, HET3-X and HET3-Y.

25 In a further aspect HET-3 is selected HET3-T, HET3-V, HET3-Y and HET3-W.

In a further aspect HET-3 is selected HET3-V, and HET3-Y.

In a further aspect HET-3 is selected from HET3-Z, HET3-AA, HET3-AB, HET3-AC, HET3-AD, HET3-AE, HET3-AF, HET3-AG and HET3-AH.

When m = 1, in one aspect R1a is selected from R1a1; in another aspect R1a is selected
30 from R1a2; in a further aspect R1a is selected from R1a3, in a further aspect R1a is selected from R1a4 and in a further aspect R1a is selected from R1a5.

When m = 2, in one aspect both groups R1a are independently selected from the same group R1a1 to R1a5. In a further aspect when m = 2, each R1a is independently selected from

different groups R_{1a1} to R_{1a5} .

Conveniently m is 1 or 2. In one aspect, preferably m is 1. In another aspect, preferably m is 2.

Particular values for R_{1a} when selected from R_{1a1} are $AR1$ and $AR2$, more particularly $AR2$.

Particular values for R_{1a} when selected from R_{1a2} are cyano and $-C(=W)NR_vR_w$ [wherein W is O or S, R_v and R_w are independently H, or (1-4C)alkyl and wherein R_v and R_w taken together with the amide or thioamide nitrogen to which they are attached can form a 5-7 membered ring optionally with an additional heteroatom selected from N, O, S(O) $_n$ in place of 1 carbon atom of the so formed ring; wherein when said ring is a piperazine ring, the ring may be optionally substituted on the additional nitrogen by a group selected from (1-4C)alkyl (optionally substituted on a carbon not adjacent to the nitrogen), (1-4C)cycloalkyl, (1-4C)acyl, $-COO(1-4C)alkyl$, S(O) $_n(1-4C)alkyl$ (wherein $n = 1$ or 2); $-COOAR1$, $-CS(1-4C)alkyl$ and $-C(=S)O(1-4C)alkyl$; wherein any (1-4C)alkyl, (1-4C)acyl and (1-4C)cycloalkyl is optionally substituted by cyano, hydroxy or halo]. More particular values for R_{1a} when selected from R_{1a2} are cyano, formyl, $-COO(1-4C)alkyl$, $-C(=O)NH_2$, $-(C=O)piperazine$ and $-(C=O)morpholine$.

Particular values for R_{1a} when selected from R_{1a3} are (1-10C)alkyl {optionally substituted by one or more groups (including geminal disubstitution) each independently selected from hydroxy, (1-10C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkylcarbonyl, phosphoryl [$-O-P(O)(OH)_2$, and mono- and di-(1-4C)alkoxy derivatives thereof], phosphiryl [$-O-P(OH)_2$ and mono- and di-(1-4C)alkoxy derivatives thereof], and amino; and/or optionally substituted by one group selected from carboxy, cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-6C)alkanoylamino-, (1-4C)alkoxycarbonylamino-, N-(1-4C)alkyl-N-(1-6C)alkanoylamino-, $-C(=W)NR_vR_w$ [wherein W is O, R_v and R_w are independently H, or (1-4C)alkyl and wherein R_v and R_w taken together with the amide nitrogen to which they are attached can form a morpholine, pyrrolidine, piperidine or piperazine ring; wherein when said ring is a piperazine ring, the ring may be optionally substituted on the additional nitrogen by a group selected from (1-4C)alkyl and (1-4C)acyl], (1-4C)alkylS(O) $_q$, (q is 0, 1 or 2), $AR2$, $AR2-O-$, $AR2-NH-$, and also $AR2a$, $AR2b$ versions of $AR2$ containing groups}; wherein any (1-4C)alkyl and (1-4C)acyl present in any substituent on R_{1a3} may itself be

substituted by one or two groups independently selected from cyano, hydroxy, halo, amino, (1-4C)alkylamino and di(1-4C)alkylamino, provided that such a substituent is not on a carbon adjacent to a heteroatom atom if present;

More particular values for R_{1a} when selected from R_{1a3} are (1-10C)alkyl { optionally
 5 substituted by one or more groups (including geminal disubstitution) each independently
 ... selected from hydroxy, (1-10C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkoxy-
 (1-4C)alkoxy-(1-4C)alkoxy, phosphoryl [-O-P(O)(OH)₂], and mono- and di-(1-4C)alkoxy
 derivatives thereof], phosphinyl [-O-P(OH)₂] and mono- and di-(1-4C)alkoxy derivatives
 thereof], carboxy, amino, (1-4C)alkylamino, di(1-4C)alkylamino, (1-4C)alkylS(O)_q
 10 (preferably where q=2), AR₂ and AR_{2b}. More particular values for R_{1a} when selected from
 R_{1a3} are (1-6C)alkyl substituted as hereinbefore described. Even more particular values for
 R_{1a} when selected from R_{1a3} are (1-4C)alkyl substituted as hereinbefore described.

Particular values for R_{1a} when selected from R_{1a4} are R₁₄C(O)O(1-6C)alkyl- wherein
 R₁₄ is selected from AR₁, AR₂, AR_{2a}, AR_{2b} and (1-10C)alkyl (optionally substituted by one
 15 or more substituents independently selected from OH and di (1-4C)alkylamino. More
 particular values for R₁₄ are AR_{2a}, AR_{2b} and (1-6C)alkyl substituted with hydroxy. More
 particular values for R₁₄ are AR_{2a}, AR_{2b} and (1-4C)alkyl substituted with hydroxy.

Particular values for R_{1a} when selected from R_{1a5} are fluoro, chloro and hydroxy.

Particular values for other substituents (which may be used where appropriate with
 20 any of the definitions and embodiments disclosed hereinbefore or hereinafter) are :-
 a) in one aspect R₇ and R₈ are independently H or (1-4C)alkyl
 b) in a further aspect R₇ and R₈ taken together with the nitrogen to which they are
 attached form a 5-7 membered ring, optionally substituted as defined hereinbefore or
 hereinafter

25 c) preferably R₇ and R₈ taken together with the nitrogen to which they are attached form
 a pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl ring
 d) preferable optional substituents on R₇ and R₈ as a pyrrolidinyl, piperidinyl, piperazinyl
 or morpholinyl ring are (1-4C)alkyl and (1-4C)acyl, wherein the (1-4C)alkyl or (1-4C)acyl
 group itself may be optionally substituted with one or two substituents selected from hydroxy,
 30 amino, (1-4C)alkylamino and di(1-4C)alkylamino

e) In one aspect R₉ is selected from R_{9a}, preferably selected from AR₂, AR_{2a} and AR_{2b}

f) In another aspect R₉ is selected from R_{9b}, preferably selected from -C(=W)NR_vR_w,
 wherein wherein W is O, R_v and R_w are independently H, or (1-4C)alkyl and wherein R_v and

Rw taken together with the amide nitrogen to which they are attached can form a morpholine, pyrrolidine, piperidine or piperazine ring; wherein when said ring is a piperazine ring, the ring may be optionally substituted on the additional nitrogen by a group selected from (1-4C)alkyl and (1-4C)acyl, and wherein any (1-4C)alkyl and (1-4C)acyl may itself be substituted by one or two groups independently selected from cyano, hydroxy, halo, amino, (1-4C)alkylamino and di(1-4C)alkylamino, provided that such a substituent is not on a carbon adjacent to a heteroatom atom if present


g) In a further aspect R9 is selected from R9c, wherein R9c is (1-6C)alkyl {optionally substituted by one, two or three groups (including geminal disubstitution) each independently selected from hydroxy, (1-10C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkylcarbonyl, phosphoryl [-O-P(O)(OH)₂], and mono- and di-(1-4C)alkoxy derivatives thereof], phosphiryl [-O-P(OH)₂ and mono- and di-(1-4C)alkoxy derivatives thereof], and amino; and/or optionally substituted by one group selected from carboxy, cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-6C)alkanoylamino-, (1-4C)alkoxycarbonylamino-, N-(1-4C)alkyl-N-(1-6C)alkanoylamino-, -C(=W)NR_vR_w [wherein W is O, R_v and R_w are independently H, or (1-4C)alkyl and wherein R_v and R_w taken together with the amide nitrogen to which they are attached can form a morpholine, pyrrolidine, piperidine or piperazine ring; wherein when said ring is a piperazine ring, the ring may be optionally substituted on the additional nitrogen by a group selected from (1-4C)alkyl and (1-4C)acyl], (1-4C)alkylS(O)_q- (q is 0, 1 or 2), AR₂, AR₂-O-, AR₂-NH-, and also AR_{2a}, AR_{2b} versions of AR₂ containing groups}; wherein any (1-4C)alkyl and (1-4C)acyl present in any substituent on R9c may itself be substituted by one or two groups independently selected from cyano, hydroxy, halo, amino, (1-4C)alkylamino and di(1-4C)alkylamino, provided that such a substituent is not on a carbon adjacent to a heteroatom atom if present.

h) In a further aspect R9 is selected from R9c, wherein R9c is (1-6C)alkyl {optionally substituted by one, two or three groups (including geminal disubstitution) each independently selected from hydroxy, (1-10C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxy, phosphoryl [-O-P(O)(OH)₂], and mono- and di-(1-4C)alkoxy derivatives thereof], phosphiryl [-O-P(OH)₂ and mono- and di-(1-4C)alkoxy derivatives thereof], carboxy, amino, (1-4C)alkylamino, di(1-4C)alkylamino, (1-4C)alkylS(O)_q (preferably where q=2), AR₂ and AR_{2b}. More particular values for R9c is (1-4C)alkyl,

optionally substituted as hereinbefore described.

- i) In a further aspect R9 is selected from R9d wherein R9d is R14C(O)O(1-6C)alkyl- and R14 is selected from AR1, AR2, AR2a, AR2b and (1-10C)alkyl (optionally substituted by one or two substituents independently selected from OH and di (1-4C)alkylamino). Particular values for R14 are AR2a, AR2b and (1-6C)alkyl substituted with hydroxy. More particular values for R14 are AR2a, AR2b and (1-4C)alkyl substituted with hydroxy.
- j) Particular values for R21 is R14C(O)O(2-6C)alkyl-, wherein R14 is preferably selected from AR1, AR2, AR2a, AR2b and (1-10C)alkyl (optionally substituted by one or two substituents independently selected from OH and di (1-4C)alkylamino).
- 10 k) Preferably R22 is cyano.
- l) Particularly preferred values for AR2, AR2a and AR2b groups are those containing a basic nitrogen, for example pyridine, pyrrolidine, piperazine and piperidine, optionally substituted as hereinbefore defined.

- 15 In one embodiment is provided a compound of the formula (IA) or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof,



(IA)

- 20 wherein group C is group D; R2a and R6a are both hydrogen; R2b and R6b are independently hydrogen or fluorine; and R4 is selected from HET-3.

In another embodiment is provided a compound of the formula (IA) or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, wherein group C is group D; R2a and R6a are both hydrogen; R2b and R6b are independently hydrogen or fluorine; and R4 is selected from HET3-T, HET3-U, HET3-V, HET3-W, HET3-X and HET3-Y.

- In another embodiment is provided a compound of the formula (IA) or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, wherein group C is group D; R2a and R6a are both hydrogen; R2b and R6b are independently hydrogen or fluorine; and R4 is selected from HET3-Z, HET3-AA, HET3-AB, HET3-AC, HET3-AD,
- 30

HET3-AE, HET3-AF, HET3-AG and HET3-AH.

In another embodiment is provided a compound of the formula (IA) or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, wherein group C is group D; R_{2a} and R_{6a} are both hydrogen; R_{2b} and R_{6b} are independently hydrogen or fluorine; R₄ is selected from HET3-Z, HET3-AA, HET3-AB, HET3-AC, HET3-AD, HET3-AE, HET3-AF, HET3-AG and HET3-AH; m=1 and R_{1a} is selected from R_{1a3}.

In another embodiment is provided a compound of the formula (IA) or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, wherein group C is group E; R_{2a} and R_{6a} are both hydrogen; R_{2b} and R_{6b} are independently hydrogen or fluorine; and R₄ is selected from HET3-T, HET3-U, HET3-V, HET3-W, HET3-X and HET3-Y.

In another embodiment is provided a compound of the formula (IA) or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, wherein group C is group E; R_{2a} and R_{6a} are both hydrogen; R_{2b} and R_{6b} are independently hydrogen or fluorine; and R₄ is selected from HET3-Z, HET3-AA, HET3-AB, HET3-AC, HET3-AD, HET3-AE, HET3-AF, HET3-AG and HET3-AH.

In another embodiment is provided a compound of the formula (IA) or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, wherein group C is group E; R_{2a} and R_{6a} are both hydrogen; R_{2b} and R_{6b} are independently hydrogen or fluorine; R₄ is selected from HET3-Z, HET3-AA, HET3-AB, HET3-AC, HET3-AD, HET3-AE, HET3-AF, HET3-AG and HET3-AH; m=1 and R_{1a} is selected from R_{1a3}.

In another embodiment is provided a compound of the formula (IA) or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, wherein group C is group D; R_{2a} and R_{6a} are both hydrogen; R_{2b} and R_{6b} are independently hydrogen or fluorine; R₄ is selected from HET3-T, HET3-U, HET3-V, HET3-W, HET3-X and HET3-Y, R_{1b} is selected from Z_d and Z_f, u and v are independently 0 or 1 and R_T is selected from hydrogen, halogen, cyano, methyl, fluoromethyl, chloromethyl, bromomethyl, cyanomethyl, azidomethyl, hydroxymethyl, difluoromethyl, and trifluoromethyl.

In another embodiment is provided a compound of the formula (IA) or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, wherein group C is group D; R_{2a} and R_{6a} are both hydrogen; R_{2b} and R_{6b} are independently hydrogen or fluorine; and R₄ is selected HET3-Z, HET3-AA, HET3-AB, HET3-AC, HET3-AD, HET3-AE, HET3-AF, HET3-AG and HET3-AH, R_{1b} is selected from Z_d and Z_f, u and v are independently 0 or 1 and R_T is selected from hydrogen, halogen, cyano, methyl,

fluoromethyl, choromethyl, bromomethyl, cyanomethyl, azidomethyl, hydroxymethyl, difluoromethyl, and trifluoromethyl.

In another embodiment is provided a compound of the formula (IA) or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, wherein group C is
5 group D; R_{2a} and R_{6a} are both hydrogen; R_{2b} and R_{6b} are independently hydrogen or fluorine; R₄ is selected from HET3-Z, HET3-AA, HET3-AB, HET3-AC, HET3-AD, HET3-AE, HET3-AF, HET3-AG and HET3-AH; m=1, R_{1a} is selected from R_{1a3}, R_{1b} is selected from Z_d and Z_f, u and v are independently 0 or 1 and RT is selected from hydrogen, halogen, cyano, methyl, fluoromethyl, choromethyl, bromomethyl, cyanomethyl, azidomethyl,
10 hydroxymethyl, difluoromethyl, and trifluoromethyl

In another embodiment is provided a compound of the formula (IA) or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, wherein group C is group E; R_{2a} and R_{6a} are both hydrogen; R_{2b} and R_{6b} are independently hydrogen or fluorine; and R₄ is selected from HET3-T, HET3-U, HET3-V, HET3-W, HET3-X and HET3-Y, R_{1b}
15 is selected from Z_d and Z_f, u and v are independently 0 or 1 and RT is selected from hydrogen, halogen, cyano, methyl, fluoromethyl, choromethyl, bromomethyl, cyanomethyl, azidomethyl, hydroxymethyl, difluoromethyl, and trifluoromethyl

In another embodiment is provided a compound of the formula (IA) or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, wherein group C is
20 group E; R_{2a} and R_{6a} are both hydrogen; R_{2b} and R_{6b} are independently hydrogen or fluorine; and R₄ is selected from HET3-Z, HET3-AA, HET3-AB, HET3-AC, HET3-AD, HET3-AE, HET3-AF, HET3-AG and HET3-AH, R_{1b} is selected from Z_d and Z_f, u and v are independently 0 or 1 and RT is selected from hydrogen, halogen, cyano, methyl, fluoromethyl, choromethyl, bromomethyl, cyanomethyl, azidomethyl, hydroxymethyl,
25 difluoromethyl, and trifluoromethyl

In another embodiment is provided a compound of the formula (IA) or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, wherein group C is group E; R_{2a} and R_{6a} are both hydrogen; R_{2b} and R_{6b} are independently hydrogen or fluorine; R₄ is selected from HET3-Z, HET3-AA, HET3-AB, HET3-AC, HET3-AD, HET3-AE,
30 HET3-AF, HET3-AG and HET3-AH; m=1, R_{1a} is selected from R_{1a3}, R_{1b} is selected from Z_d and Z_f, u and v are independently 0 or 1 and RT is selected from hydrogen, halogen, cyano, methyl, fluoromethyl, choromethyl, bromomethyl, cyanomethyl, azidomethyl, hydroxymethyl, difluoromethyl, and trifluoromethyl.

In all of the above definitions the preferred compounds are as shown in formula (IA).

Particular compounds of the present invention include each individual compound described in the Examples, especially Example 1.

Process section:

5 In a further aspect the present invention provides a process for preparing a compound of invention or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof. It will be appreciated that during certain of the following processes certain substituents may require protection to prevent their undesired reaction. The skilled chemist will appreciate when such protection is required, and how such protecting groups may be put in place, and
10 later removed.

For examples of protecting groups see one of the many general texts on the subject, for example, 'Protective Groups in Organic Synthesis' by Theodora Green (publisher: John Wiley & Sons). Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting
15 group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.

Thus, if reactants include, for example, groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl
20 group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an
25 aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *t*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulfuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed; for
30 example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *t*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon. Resins may also be used as a protecting group.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

A compound of the invention, or a pharmaceutically-acceptable salt or an *in vivo* hydrolysable ester thereof, may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Such processes, when used to prepare a compound of the invention, or a pharmaceutically-acceptable salt or an *in vivo* hydrolysable ester thereof, are provided as a further feature of the invention and are illustrated by the following representative examples. Necessary starting materials may be obtained by standard procedures of organic chemistry (see, for example, Advanced Organic Chemistry (Wiley-Interscience), Jerry March or Houben-Weyl, Methoden der Organischen Chemie). The preparation of such starting materials is described within the accompanying non-limiting Examples. Alternatively, necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist. Information on the preparation of necessary starting materials or related compounds (which may be adapted to form necessary starting materials) may also be found in the certain Patent Application Publications, the contents of the relevant process sections of which are hereby incorporated herein by reference; for example WO 94/13649; WO 98/54161; WO 99/64416; WO 99/64417; WO 00/21960; WO 01/40222.

In particular we refer to our PCT patent applications WO 99/64417 and WO 00/21960 wherein detailed guidance is given on convenient methods for preparing oxazolidinone compounds.

The skilled organic chemist will be able to use and adapt the information contained
5 and referenced within the above references, and accompanying Examples therein and also the
Examples herein, to obtain necessary starting materials, and products. For example, the
skilled chemist will be able to apply the teaching herein for compounds of formula (I) in
which a pyrimidyl-phenyl group is present (that is when group C is group D) to prepare
compounds in which a pyridyl-phenyl group is present (that is when group C is group E) as
10 heereinbefore defined and *vice versa*.

Thus, the present invention also provides that the compounds of the invention and
pharmaceutically-acceptable salts and *in vivo* hydrolysable esters thereof, can be prepared by
a process (a) to (j) as follows (wherein the variables are as defined above unless otherwise
15 stated):

- a) by modifying a substituent in, or introducing a substituent into another compound of
the invention by using standard chemistry (see for example, Comprehensive Organic
Functional Group Transformations (Pergamon), Katritzky, Meth-Cohn & Rees or Advanced
Organic Chemistry (Wiley-Interscience), Jerry March or Houben-Weyl, Methoden der
20 Organischen Chemie); for example:
an acylamino group may be converted into a thioacylamino group;
an acylamino group or thioacylamino group may be converted into another acylamino or
thioacylamino; heterocyclyl for instance tetrazolyl or thiazolyl, or heterocyclylamino group
(optionally substituted or protected on the amino-nitrogen atom);
25 an acyloxy group may be converted into a hydroxy group or into the groups that may be
obtained from a hydroxy group (either directly or through the intermediacy of a hydroxy
group);
an alkyl halide such as alkylbromide or alkyl iodide may be converted into an alkyl fluoride or
nitrile;
30 an alkyl sulfonate such as alkyl methanesulfonate may be converted into an alkyl fluoride or
nitrile;
an alkylthio group such as methylthio may be converted into a methanesulfinyl
or methanesulfonyl group;

an arylthio group such as phenylthio may be converted into a benzenesulfinyl or benzenesulfonyl group;

an amidino or guanidino group may be converted into a range of 2-substituted 1,3-diazoles and 1,3-diazines;

5 an amino group may be converted for instance into acylamino or thioacylamino for instance an acetamide (optionally substituted), alkyl- or dialkyl-amino and thence into a further range of N-alkyl-amine derivatives, sulfonylamino, sulfinylamino, amidino, guanidino, arylamino, heteroaryl-amino, N-linked heterocyclic for instance an optionally 4-substituted 1,2,3-triazol-1-yl group;

10 an aryl- or heteroaryl-halide group such as an aryl- or hetero-aryl chloride or bromide or iodide may be converted by transition metal mediated coupling, especially Pd(0) mediated coupling into a range of aryl-, heteroaryl, alkenyl, alkynyl, acyl, alkylthio, or alkyl- or dialkyl-amino substituted aryl or heteroaryl groups;

an aryl- or heteroaryl-sulfonate group such as an aryl- or hetero-aryl trifluoromethanesulfonate
15 may be converted by transition metal mediated coupling, especially Pd(0) mediated coupling into a range of aryl-, heteroaryl, alkenyl, alkynyl, acyl, alkylthio, or alkyl- or dialkyl-amino substituted aryl or heteroaryl groups;

an aryl- or heteroaryl-halide group such as an aryl- or hetero-aryl chloride or bromide or iodide may be converted by transition metal mediated coupling, especially Pd(0) mediated coupling
20 into a range of trialkyltin, dialkylboronate, trialkoxysilyl, substituted aryl or heteroaryl groups useful as intermediates for the synthesis of compounds of the invention;


an azido group may be converted for instance into a 1,2,3-triazolyl or amine and thence by methods that are well known in the art into any of the range common amine derivatives such as acylamino for instance acetamido group;

25 a carboxylic acid group may be converted into trifluoromethyl, hydroxymethyl, alkoxy-carbonyl, aminocarbonyl optionally substituted on nitrogen, formyl, or acyl groups;
a cyano group may be converted into a tetrazole, or an imidate, an amidine, an amidrazone, an N-hydroxyamidrazone, an amide, a thioamide, an ester, or an acid and thence by methods that are well known in the art into any of the range of heterocycles derived from such nitrile
30 derivatives;

a hydroxy group may be converted for instance into an alkoxy, cyano, azido, alkylthio, keto and oximino, fluoro, bromo, chloro, iodo, alkyl- or aryl-sulfonyloxy for instance trifluoromethanesulfonate, methanesulfonate, or tosylsulfonate, silyloxy ; acylamino or


- thioacylamino, for instance an acetamide (optionally substituted or protected on the amido-nitrogen atom); acyloxy, for instance an acetoxy; phosphono-oxy, heterocyclylamino (optionally substituted or protected on the amino-nitrogen atom), for instance an isoxazol-3-ylamino or a 1,2,5-thiadiazol-3-ylamino; heterocyclyl linked through nitrogen (optionally substituted on a carbon other than a carbon atom adjacent to the linking nitrogen ring atom), for instance an optionally 4-substituted 1,2,3-triazol-1-yl; or amidino, for instance an 1-(N-cyanoimino)ethylamino group; such conversions of the hydroxy group taking place directly (for instance by acylation or Mitsunobu reaction) or through the intermediacy of one or more derivatives (for instance a mesylate or an azide);
- 10 a silyloxy group may be converted into a hydroxy group or into the groups that may be obtained from a hydroxy group (either directly or through the intermediacy of a hydroxy group);
- a keto group may be converted into a hydroxy, thiocarbonyl, oximino, or difluoro group;
- a nitro-group may be converted into an amino group and thence by methods that are well known in the art into any of the range common amine derivatives such as acylamino for instance acetamido group;
- 15 a 2-, 4-, or 6-pyridyl or 2-, 4-, or 6-pyrimidyl halide such as chloride or sulfonate such as mesylate substituent may be converted into alkoxy, alkythio, amino, alkylamino, dialkylamino, or N-linked heterocyclic substituents;
- 20 Moreover, an optionally substituted heteroaromatic ring D or E may be converted into another heteroaromatic ring D or E by introduction of a new substituent (R2a, R3a, or R6a) or by refunctionalisation of an existing substituent (R2a, R3a, or R6a)
- a heterocyclylamino group (optionally substituted or protected on the amino-nitrogen atom) may be converted into another heterocyclyl amino group (optionally substituted or protected on the amino-nitrogen atom) by refunctionalisation, for instance by protection or deprotection,
- 25 of the amino-nitrogen atom, by introduction of a new ring substituent, or by refunctionalisation of an existing ring substituent;
- a heterocyclyl group linked through nitrogen (optionally substituted on a carbon other than a carbon atom adjacent to the linking nitrogen ring atom) may be converted into another
- 30 heterocyclyl group linked through nitrogen (optionally substituted on a carbon other than a carbon atom adjacent to the linking nitrogen ring atom) by introduction of a new ring substituent or by refunctionalisation of an existing ring substituent, for instance by modifying the 4-substituent of a 4-substituted 1,2,3-triazol-1-yl group.

For instance, examples drawn from the methods for conversion of a hydroxy group into an optionally substituted triazole group are illustrated by the scheme:




- 5 Examples drawn from the range of regioselective methods that proceed under very mild conditions are illustrated by processes (h), (i), and (j).
- b) by reaction of a molecule of a compound of formula (IIa) [wherein X is a leaving group useful in palladium coupling (for example chloride, bromide, iodide, trifluoromethylsulfonyloxy, trimethylstannyl, trialkoxysilyl, or a boronic acid residue) and in this instance A is either N or C-R₃a] with a molecules of a compound of formula (IIb) (wherein X' is a leaving group useful in palladium coupling, for example chloride, bromide, iodide, trifluoromethylsulfonyloxy, trimethylstannyl, trialkoxysilyl, or a boronic acid residue) wherein X and X' are chosen such that an aryl-aryl, heteroaryl-aryl, or heteroaryl-heteroaryl bond replaces the aryl-X (or heteroaryl-X) and aryl-X' (or heteroaryl-X') bonds. Such

methods are now well known, see for instance J.K. Stille, *Angew Chem. Int. Ed. Eng.*, 1986, 25, 509-524; N. Miyaura and A Suzuki, *Chem. Rev.*, 1995, 95, 2457-2483, D. Baranano, G. Mann, and J.F. Hartwig, *Current Org. Chem.*, 1997, 1, 287-305, S.P. Stanforth, *Tetrahedron*, 54 1998, 263-303, and P.R. Parry, C. Wang, A.S. Batsanov, M.R. Bryce, and B. Tarbit, *J. Org. Chem.*, 2002, 67, 7541-7543.




The leaving groups X and X' are chosen to be different and to lead to the desired cross-coupling products of formula (I).

10 For example



The pyridines, pyrimidines, and aryl oxazolidinones required as reagents for process b) or as intermediates for the preparation of reagents for process b) may be prepared by standard organic methods, for instance by methods analogous to those set out in process sections c) to j). Methods for the introduction and interconversion of Groups X and X' are well known in the art.

c) by reaction of a heterobiaryl derivative (III) carbamate with an appropriately substituted oxirane to form an oxazolidinone ring;




5


Variations on this process in which the carbamate is replaced by an isocyanate or by an amine or/and in which the oxirane is replaced by an equivalent reagent $X-CH_2CH(O\text{-optionally protected})CH_2R_{1b}$ where X is a displaceable group are also well known in the art.

For example,

10



(d) by reaction of a compound of formula (VI) :



15

where X is a replaceable substituent - such as chloride, bromide, iodide, trifluoromethylsulfonyloxy, trimethylstannyl, trialkoxysilyl, or a boronic acid residue with a compound of the formula (VII):




(VII)

20

wherein T-X' is HET3 as herein above defined and X' is a replaceable C-linked substituent - such as chloride, bromide, iodide, trifluoromethylsulfonyloxy, trimethylstannyl, trialkoxysilyl, or a boronic acid residue; wherein the substituents X and X' are chosen to be complementary


pairs of substituents known in the art to be suitable as complementary substrates for coupling reactions catalysed by transition metals such as palladium(0);

(d(i)) by reaction catalysed by transition metals such as palladium(0) of a compound of formula (VIII):




(VIII)

wherein X is a replaceable substituent - such as chloride, bromide, iodide, trifluoromethylsulfonyloxy, trimethylstannyl, trialkoxysilyl, or a boronic acid residue with a compound of the formula (IX) (*Tetrahedron Letts.*, 2001, 42(22), 3681-3684);



(IX)

(d(ii)) by reaction of a compound of formula (X):





(X)

X is a replaceable substituent - such as chloride, bromide, iodide, trifluoromethylsulfonyloxy - with a compound of the formula (XI):


T-H

(XI)


wherein T-H is an amine R_7R_8NH , an alcohol $R_{10}OH$, or an azole with an available ring-NH group to give compounds (XIIa), (XIIb), or (XIIc) wherein in this instance A is nitrogen or C- R_{3a} and A' is nitrogen or carbon optionally substituted with one or more groups R_{1a} ;



(e) by reaction of a compound of formula (XIII):




- 10 wherein X1 and X2 here are independently optionally substituted heteroatoms drawn in combination from O, N, and S such that C(X1)X2 constitutes a substituent that is a carboxylic acid derivative substituent with a compound of the formula (XIV) and X3 and X4 are independently optionally substituted heteroatoms drawn in combination from O, N, and S:



(XIV)


- 15 and wherein one of C(X1)X2 and C(X3)X4 constitutes an optionally substituted hydrazide, thiohydrazide, or amidrazone, hydroximate, or hydroxamine and the other one of C(X1)X2 and C(X3)X4 constitutes an optionally substituted acylating, thioacylating, or imidoylating agent such that C(X1)X2 and C(X3)X4 may be condensed together to form a
- 20 1,2,4-heteroatom 5-membered heterocycle containing 3 heteroatoms drawn in combination from O, N, and S, for instance thiadiazole, by methods well-known in the art;

(e (i)) by reaction of a compound of formula (XV):




(XV)

wherein X_2 is a displaceable group such as ethoxy or diphenylphosphonyloxy with a source of azide anion such as sodium azide to give a tetrazole (XVI)




(XVI)

Alternatively nitriles of formula (XVII)




(XVII)

10 may be reacted directly with azides such as ammonium azide or trialkylstannylazides to give tetrazoles (XVI, $R_1a = H$) that are subsequently alkylated with groups $R_1a \neq H$ to give tetrazoles (XVIIIa) and (XVIIIb);




(XVIIIa)




(XVIIIb)

15 (f) by reaction of a compound of formula (XIX):



(XIX)

with a compound of the formula (XX):




(XX)

wherein one of C(X5)X6 and C(X7)X8 constitutes an optionally substituted alpha-(leaving-group-substituted)ketone, wherein the leaving group is for example a halo-group or an (alkyl or aryl)-sulfonyloxy-group, and the other one of C(X5)X6 and C(X7)X8 constitutes an optionally substituted amide, thioamide, or amidine, such that C(X5)X6 and C(X7)X8 are groups that may be condensed together to form a 1,3-heteroatom 5-membered heterocycle containing 2 heteroatoms drawn in combination from O, N, and S, for instance thiazole, by methods well-known in the art;


10 (g) for HET as optionally substituted 1,2,3-triazoles, compounds of the formula (I) may be made by cycloaddition via the azide (wherein e.g. Y in (II) is azide) to acetylenes, or to acetylene equivalents such as optionally substituted cyclohexa-1,4-dienes or optionally substituted ethylenes bearing eliminatable substituents such as arylsulfonyl;

(h) for HET as 4-substituted 1,2,3-triazole compounds of formula (I) may be made by
15 reacting aminomethyloxazolidinones with 1,1-dihaloketone sulfonylhydrazones (Sakai, Kuniyazu; Hida, Nobuko; Kondo, Kiyosi; *Bull. Chem. Soc. Jpn.*, **59**, 1986, 179-183; Sakai, Kunikazu; Tsunemoto, Daiei; Kobori, Takeo; Kondo, Kiyoshi; Hido, Noboko EP 103840 A2 19840328);




20 (i) for HET as 4-substituted 1,2,3-triazole compounds of formula (I) may also be made by reacting azidomethyl oxazolidinones with terminal alkynes using Cu(I) catalysis in e.g. aqueous alcoholic solution at ambient temperatures to give 4-substituted 1,2,3-triazoles (V.V. Rostovtsev, L.G. Green, V.V. Fokin, and K.B. Sharpless, *Angew. Chem. Int. Ed.*, 2002, 41, 2596-2599):

25




(j) for HET as 4-halogenated 1,2,3-triazole compounds of formula (I) may also be made by reacting azidomethyl oxazolidinones with halovinylsulfonyl chlorides at a temperature between 0 °C and 100 °C either neat or in an inert diluent such as chlorobenzene, chloroform or dioxan.



A similar cycloaddition reaction with an unrelated azide to give an unrelated triazole has been disclosed in the literature for the case where the halogen in the vinylsulfonylchloride reagent shown above is bromine (C. S. Rondestvedt, Jr. and P.K. Chang, *J. Amer. Chem. Soc.*, 77, 1955, 6532-6540; preparation of 1-bromo-1-ethenesulfonyl chloride by C. S. Rondestvedt, Jr., *J. Amer. Chem. Soc.*, 76, 1954, 1926-1929). However, a reaction of vinylsulfonyl chloride failed to stop at the desired product and gave instead an unwanted by-product. Moreover, the factors that govern the formation of either the undesired triazole by elimination of the elements of H-Halogen from the intermediate cycloadduct or the desired triazole by elimination of the elements of HCl and SO₂ from the intermediate cycloadduct are not set out in the literature.

We have now surprisingly found that, when the halogen is chlorine, that is when the reagent is the compound 1-chloro-1-ethenesulfonyl chloride



the cycloaddition reaction is highly regioselective and gives a good yield of the desired product. Furthermore the reagent 1-chloro-1-ethenesulfonyl chloride is novel. Therefore a further aspect of the invention comprises the compound 1-chloro-1-ethenesulfonyl chloride. Another aspect of the invention comprises the use of 1-chloro-1-ethenesulfonyl chloride in a cycloaddition reaction with an azide to form a 4-chloro-1,2,3-triazole. A further aspect of the invention comprises use of 1-chloro-1-ethenesulfonyl chloride with an azide derivative in a process to form a compound of the formula (I) wherein R1b is 4-chloro-1,2,3-triazole, or R4 is 4-chloro-HET3-AB.

The cycloaddition reaction with 1-chloro-1-ethenesulfonyl chloride with an azide derivative in a process to form a compound of the formula (I) wherein R1b is 4-chloro-1,2,3-

triazole and or R4 is 4-chloro-HET3-AB is carried out at 0 °C and 100 °C , preferably at room temperature, either in an inert solvent, preferably chlorobenzene, chloroform, or dioxan, or more preferably without a solvent.

5 The removal of any protecting groups, the formation of a pharmaceutically-acceptable salt and/or the formation of an in-vivo hydrolysable ester are within the skill of an ordinary organic chemist using standard techniques. Furthermore, details on the these steps, for example the preparation of in-vivo hydrolysable ester prodrugs has been provided, for example, in the section above on such esters.

10 When an optically active form of a compound of the invention is required, it may be obtained by carrying out one of the above procedures using an optically active starting material (formed, for example, by asymmetric induction of a suitable reaction step), or by resolution of a racemic form of the compound or intermediate using a standard procedure, or by chromatographic separation of diastereoisomers (when produced). Enzymatic techniques
15 may also be useful for the preparation of optically active compounds and/or intermediates.

 Similarly, when a pure regioisomer of a compound of the invention is required, it may be obtained by carrying out one of the above procedures using a pure regioisomer as a starting material, or by resolution of a mixture of the regioisomers or intermediates using a standard procedure.

20 According to a further feature of the invention there is provided a compound of the invention, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof for use in a method of treatment of the human or animal body by therapy.

 According to a further feature of the present invention there is provided a method for producing an antibacterial effect in a warm blooded animal, such as man, in need of such
25 treatment, which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof.

 The invention also provides a compound of the invention, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof, for use as a medicament; and the use of
30 a compound of the invention of the present invention, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof, in the manufacture of a medicament for use in the production of an antibacterial effect in a warm blooded animal, such as man.

In order to use a compound of the invention, an in-vivo hydrolysable ester or a pharmaceutically-acceptable salt thereof, including a pharmaceutically-acceptable salt of an in-vivo hydrolysable ester, (hereinafter in this section relating to pharmaceutical composition "a compound of this invention") for the therapeutic (including prophylactic) treatment of mammals including humans, in particular in treating infection, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the invention, an in-vivo hydrolysable ester or a pharmaceutically-acceptable salt thereof, including a pharmaceutically-acceptable salt of an in-vivo hydrolysable ester, and a pharmaceutically-acceptable diluent or carrier.

The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration as eye-drops, for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, sub-lingual, intramuscular or intramuscular dosing or as a suppository for rectal dosing).

In addition to the compounds of the present invention, the pharmaceutical composition of this invention may also contain (ie through co-formulation) or be co-administered (simultaneously, sequentially or separately) with one or more known drugs selected from other clinically useful antibacterial agents (for example, β -lactams, macrolides, quinolones or aminoglycosides) and/or other anti-infective agents (for example, an antifungal triazole or amphotericin). These may include carbapenems, for example meropenem or imipenem, to broaden the therapeutic effectiveness. Compounds of this invention may also be co-formulated or co-administered with bactericidal/permeability-increasing protein (BPI) products or efflux pump inhibitors to improve activity against gram negative bacteria and bacteria resistant to antimicrobial agents.

The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents. A pharmaceutical composition to be dosed intravenously may contain

advantageously (for example to enhance stability) a suitable bactericide, antioxidant or reducing agent, or a suitable sequestering agent.

Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.

Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin; or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxyethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such

as liquid paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

5 Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be
10 present.

The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum
15 tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavouring and preservative agents.

20 Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.

The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using
25 one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol. Solubility enhancing agents, for example cyclodextrins may be used.

30 Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile

fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.

For further information on formulation the reader is referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 50 mg to 5 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will generally contain about 200 mg to about 2 g of an active ingredient. For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 1mg and 1g of a compound of this invention, preferably between 100mg and 1g of a compound. Especially preferred is a tablet or capsule which contains between 50mg and 800mg of a compound of this invention, particularly in the range 100mg to 500mg.

In another aspect a pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection, for example an injection which contains between 0.1% w/v and 50% w/v (between 1mg/ml and 500mg/ml) of a compound of this invention.

Each patient may receive, for example, a daily intravenous, subcutaneous or intramuscular dose of 0.5 mgkg^{-1} to 20 mgkg^{-1} of a compound of this invention, the composition being administered 1 to 4 times per day. In another embodiment a daily dose of 5 mgkg^{-1} to 20 mgkg^{-1} of a compound of this invention is administered. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient may receive a daily oral dose which may be approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.

In the above other, pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the invention described herein also apply.

5 Antibacterial Activity :

The pharmaceutically-acceptable compounds of the present invention are useful antibacterial agents having a good spectrum of activity in vitro against standard Gram-positive organisms, which are used to screen for activity against pathogenic bacteria. Notably, the pharmaceutically-acceptable compounds of the present invention show activity
10 against enterococci, pneumococci and methicillin resistant strains of S.aureus and coagulase negative staphylococci, together with haemophilus and moraxella strains. The antibacterial spectrum and potency of a particular compound may be determined in a standard test system.

The (antibacterial) properties of the compounds of the invention may also be demonstrated and assessed in-vivo in conventional tests, for example by oral and/or
15 intravenous dosing of a compound to a warm-blooded mammal using standard techniques.

The following results were obtained on a standard in-vitro test system. The activity is described in terms of the minimum inhibitory concentration (MIC) determined by the agar-dilution technique with an inoculum size of 10^4 CFU/spot. Typically, compounds are active in the range 0.01 to 256 μ g/ml.

20 Staphylococci were tested on agar, using an inoculum of 10^4 CFU/spot and an incubation temperature of 37°C for 24 hours - standard test conditions for the expression of methicillin resistance.

Streptococci and enterococci were tested on agar supplemented with 5% defibrinated horse blood, an inoculum of 10^4 CFU/spot and an incubation temperature of
25 37°C in an atmosphere of 5% carbon dioxide for 48 hours - blood is required for the growth of some of the test organisms. Fastidious Gram negative organisms were tested in Mueller-Hinton broth, supplemented with hemin and NAD, grown aerobically for 24 hours at 37°C, and with an innoculum of 5×10^4 CFU/well.

For example, the following results were obtained for the compound of Example 1:

<u>Organism</u>		<u>MIC ($\mu\text{g/ml}$)</u>
Staphylococcus aureus:	MSQS	0.25
	MRQR	0.25
Streptococcus pneumoniae		<0.06
5 Enterococcus faecium		0.25
Haemophilus influenzae		2
Moraxella catarrhalis		0.25
Linezolid Resistant Streptococcus pneumoniae		0.5

- 10 MSQS = methicillin sensitive and quinolone sensitive
 MRQR = methicillin resistant and quinolone resistant

Certain intermediates and/or Reference Examples described hereinafter are within the scope of the invention and may also possess useful activity, and are provided as a further feature
 15 of the invention.

The invention is now illustrated but not limited by the following Examples in which unless otherwise stated :-

- (i) evaporations were carried out by rotary evaporation in-vacuo and work-up procedures were carried out after removal of residual solids by filtration;
- 20 (ii) operations were carried out at ambient temperature, that is typically in the range 18-26°C and without exclusion of air unless otherwise stated, or unless the skilled person would otherwise work under an inert atmosphere;
- (iii) column chromatography (by the flash procedure) was used to purify compounds and was performed on Merck Kieselgel silica (Art. 9385) unless otherwise stated;
- 25 (iv) yields are given for illustration only and are not necessarily the maximum attainable;
- (v) the structure of the end-products of the invention were generally confirmed by NMR and mass spectral techniques [proton magnetic resonance spectra were generally determined in DMSO-d₆ unless otherwise stated using a Varian Gemini 2000 spectrometer operating at a field strength of 300 MHz, or a Bruker AM250 spectrometer operating at a field strength of
 30 250 MHz; chemical shifts are reported in parts per million downfield from tetramethylsilane as an internal standard (δ scale) and peak multiplicities are shown thus: s, singlet; d, doublet; AB or dd, doublet of doublets; dt, doublet of triplets; dm, doublet of multiplets; t, triplet, m, multiplet; br, broad; fast-atom bombardment (FAB) mass spectral data were generally

obtained using a Platform spectrometer (supplied by Micromass) run in electrospray and, where appropriate, either positive ion data or negative ion data were collected]; optical rotations were determined at 589nm at 20°C for 0.1M solutions in methanol using a Perkin Elmer Polarimeter 341;

5 (vi) each intermediate was purified to the standard required for the subsequent stage and was characterised in sufficient detail to confirm that the assigned structure was correct; purity was assessed by HPLC, TLC, or NMR and identity was determined by infra-red spectroscopy (IR), mass spectroscopy or NMR spectroscopy as appropriate;


(vii) in which the following abbreviations may be used :-

10 DMF is N,N-dimethylformamide; DMA is N,N-dimethylacetamide; TLC is thin layer chromatography; HPLC is high pressure liquid chromatography; MPLC is medium pressure liquid chromatography; NMP is N-methylpyrrolidone; DMSO is dimethylsulfoxide; CDCl₃ is deuterated chloroform; MS is mass spectroscopy; ESP is electrospray; EI is electron impact; CI is chemical ionisation; APCI is atmospheric pressure chemical ionisation; EtOAc is ethyl acetate; MeOH is methanol; phosphoryl is (HO)₂-P(O)-O-; phosphiryl is (HO)₂-P-O-; Bleach

15 is "Clorox" 6.15% sodium hypochlorite;

(viii) temperatures are quoted as °C.

Example 1: (5*R*)-3-(3-Fluoro-4-(6-(2-methyl-2*H*-tetrazol-5-yl)pyrid-3-yl)phenyl)-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one




A mixture of (5*R*)-3-(3-fluoro-4-iodophenyl)-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (370 mg, 0.95 mmol), bis(pinacolato)diboron (605 mg, 2.4 mmol), and potassium acetate (326 mg, 3.3 mmol) in dimethylsulfoxide (5 mL) was degassed, flushed with nitrogen and treated with dichloro[1,1']bis(diphenylphosphino)ferrocene[palladium (II) dichloromethane adduct (69 mg, 10 mol %). The mixture was heated to 80 °C for 1.5 hours, cooled to room temperature, filtered through Celite, and extracted with ethyl acetate. The organic phase was washed with aqueous ammonium chloride solution, dried over magnesium sulfate, and evaporated to dryness. The involatile residue was purified by chromatography on silica-gel [elution with hexanes:ethyl acetate (3:2)] to give a mixture of (5*R*)-3-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,2-oxazolidin-2-one and the corresponding boronic acid (210 mg, ~0.54 mmol, 57%) that was used without further purification.

A mixture of the mixture of boronate ester and boronic acid prepared above, 5-bromo-2-(2-methyl-2*H*-tetrazol-5-yl)pyridine (160 mg, 0.67 mmol), and potassium carbonate (448 mg, 3.24 mmol) in *N,N*-dimethyl formamide and water (10 mL, 7:1) was degassed, flushed with nitrogen, and treated with *tetrakis* (triphenylphosphine) palladium (0) (62 mg, 0.054 mmol). The reaction mixture was heated at 80 °C for 1.5 hours, cooled to room temperature, filtered through Celite, extracted with ethyl acetate, dried over magnesium sulfate, and evaporated to dryness. The involatile residue was purified by chromatography on silica-gel [elution with ethyl acetate:hexanes (3:2)] to give the product as a colorless amorphous solid (140 mg, 61 %).

MS (ESP): 422.47 (MH⁺) for C₁₉H₁₆FN₉O₂

¹H-NMR (DMSO-*d*₆) δ: 3.98 (dd, 1H); 4.31 (dd, 1H); 4.47 (s, 3H); 4.86 (m, 2H); 5.18 (m, 1H); 7.45 (m, 1H); 7.61 (m, 1H); 7.74 (m, 1H); 7.77 (brs, 1H); 8.12-8.27 (m, 3H); 8.93 (s, 1H).

The intermediates for Example 1 were prepared as follows:


Acetic acid (5R)-3-(3-fluorophenyl)-1,3-oxazolidin-2-one-5-ylmethyl ester

- (5R)-3-(3-Fluorophenyl)-5-hydroxymethyl-1,3-oxazolidin-2-one (40 g, 0.189 M, see Upjohn WO 94-13649) was suspended by stirring in dry dichloromethane (400 mL) under nitrogen.
- 5 Triethylamine (21 g, 0.208 M) and 4-dimethylaminopyridine (0.6 g, 4.9 mM) were added, followed by dropwise addition of acetic anhydride (20.3 g, 0.199 M) over 30 minutes, and stirring continued at ambient temperature for 18 hours. Saturated aqueous sodium bicarbonate (250 mL) was added, the organic phase separated, washed with 2% sodium dihydrogen phosphate, dried (magnesium sulfate), filtered and evaporated to give the desired
- 10 product (49.6 g) as an oil.

MS (ESP): 254 (MH^+) for $C_{12}H_{12}FNO_4$

NMR ($CDCl_3$) δ : 2.02 (s, 3H); 3.84 (dd, 1H); 4.16 (t, 1H); 4.25 (dd, 1H); 4.32 (dd, 1H); 4.95 (m, 1H); 6.95 (td, 1H); 7.32 (d, 1H); 7.43 (t, 1H); 7.51 (d, 1H).

15 Acetic acid (5R)-3-(3-fluoro-4-iodo-phenyl)-1,3-oxazolidin-2-one-5-ylmethyl ester



- Acetic acid (5R)-3-(3-fluoro-phenyl)-1,3-oxazolidin-2-one-5-ylmethyl ester (15.2 g, 60 mM) was dissolved in a mixture of chloroform (100 mL) and acetonitrile (100 mL) under nitrogen, and silver trifluoroacetate (16.96 g, 77 mM) added. Iodine (18.07 g, 71 mM) was added in
- 20 portions over 30 minutes to the vigorously stirred solution, and stirring continued at ambient temperature for 18 hours. As reaction was not complete, a further portion of silver trifluoroacetate (2.64 g, 12 mM) was added and stirring continued for 18 hours. After filtration, the mixture was added to sodium thiosulfate solution (3%, 200 mL) and dichloromethane (200 mL), and the organic phase separated, washed with sodium thiosulfate
- 25 (200 mL), saturated aqueous sodium bicarbonate (200 mL), brine (200 mL), dried (magnesium sulfate), filtered and evaporated. The crude product was suspended in isohexane (100 mL), and sufficient diethyl ether added to dissolve out the brown impurity while stirring


for 1 hour. Filtration gave the desired product (24.3 g) as a cream solid.

MS (ESP): 380 (MH^+) for $C_{12}H_{11}FINO_4$

NMR (DMSO- d_6) δ : 2.03 (s, 3H); 3.82 (dd, 1H); 4.15 (t, 1H); 4.24 (dd, 1H); 4.30 (dd, 1H); 4.94 (m, 1H); 7.19 (dd, 1H); 7.55 (dd, 1H); 7.84 (t, 1H).

5

(5R)-3-(3-Fluoro-4-iodophenyl)-5-hydroxymethyl-1,3-oxazolidin-2-one




Acetic acid (5R)-3-(3-fluoro-4-iodophenyl)-1,3-oxazolidin-2-one-5-ylmethyl ester (30 g, 79 mM) was treated with potassium carbonate (16.4 g, 0.119 mM) in a mixture of methanol (800 mL) and dichloromethane (240 mL) at ambient temperature for 25 minutes, then immediately neutralised by the addition of acetic acid (10 mL) and water (500 mL). The precipitate was filtered, washed with water, and dissolved in dichloromethane (1.2 L), the solution washed with saturated sodium bicarbonate, and dried (magnesium sulfate). Filtration and evaporation gave the desired product (23 g).

15 MS (ESP): 338 (MH^+) for $C_{10}H_9FINO_3$

NMR (DMSO- d_6) δ : 3.53 (m, 1H); 3.67 (m, 1H); 3.82 (dd, 1H); 4.07 (t, 1H); 4.70 (m, 1H); 5.20 (t, 1H); 7.21 (dd, 1H); 7.57 (dd, 1H); 7.81 (t, 1H).

(5R)-5-Azidomethyl-3-(3-fluoro-4-iodophenyl)-1,3-oxazolidin-2-one




20

Methanesulfonyl chloride (17.9 mL) was added dropwise to a stirred solution of (5R)-3-(3-fluoro-4-iodophenyl)-5-hydroxymethyl-1,3-oxazolidin-2-one (55.8 g) and triethylamine (46.1 mL) in dry dichloromethane (800 mL) under an atmosphere of dry nitrogen and maintained below room temperature by an ice-bath. The stirred reaction mixture was allowed to warm to room temperature during 3 hours and then washed sequentially with water and brine and then dried (Na_2SO_4). Solvent was removed under reduced pressure to give the intermediate mesylate as a yellow solid (68 g) that was used without further purification.

A stirred solution in DMF (800 mL) of a mixture of the intermediate mesylate (68 g) and sodium azide (32.3 g) was heated at 75°C overnight. The mixture was allowed to cool to room temperature, diluted with water, and extracted twice with ethyl acetate. The combined extracts were washed sequentially with water and brine, and then dried (Na₂SO₄). Solvent was removed under reduced pressure to give a yellow oil that was purified by column chromatography on silica-gel [elution with ethyl acetate:hexanes (1:1)] to give the product azide as an off-white solid (49 g). The product could be further purified by trituration with ethyl acetate/hexanes.

¹H-NMR (DMSO-d₆) δ: 3.57-3.64 (dd, 1H); 3.70-3.77 (dd, 1H); 3.81-3.87 (dd, 1H); 4.06 (t, 1H); 4.78-4.84 (m, 1H); 7.05-7.09 (ddd, 1H); 7.45 (dd, 1H); 7.68-7.74 (dd, 1H).


(5R)-3-(3-Fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



A stirred solution in dioxan (300 mL) of a mixture of the (5R)-5-azidomethyl-3-(3-fluoro-4-iodophenyl)-1,3-oxazolidin-2-one (30 g) and bicyclo[2.2.1]heptadiene (30 mL) was heated under reflux overnight. The mixture was allowed to cool to room temperature and then evaporated to dryness under reduced pressure to give a brown solid. The brown solid was purified by column chromatography on silica-gel [elution with a gradient from 98:2 to 95:5 methanol:chloroform] to give the product triazole as a pale yellow solid (20 g). The product could be further purified by trituration with dichloromethane/hexanes (1:1) to give an off-white solid.

¹H-NMR (DMSO-d₆) δ: 3.86-3.92 (dd, 1H); 4.23 (t, 1H); 4.83 (d, 2H); 5.11-5.19 (m, 1H); 7.12-7.16 (dd, 1H); 7.47-7.51 (dd, 1H); 7.76 (s, 1H); 7.79-7.85 (dd, 1H); 8.16 (s, 1H).

25 3-Bromo-6-cyano-pyridine




A stirred solution of 2,5-dibromopyridine (39.465 g, 0.17 mol) in anhydrous NMP (100 mL) was treated with CuCN (14.42 g, 0.17 mol) for 20 hours at 110°C under nitrogen. The reaction mixture was cooled to 40°C and treated with aqueous sodium hydroxide (2M; 200

mL) and then with ethyl acetate (200 mL). The mixture was stirred for 1 hour and then filtered through Celite to remove the resulting precipitate. The retained solid was washed with aqueous sodium hydroxide (2M; 600 mL) and then with ethyl acetate (600 mL). The organic layers were combined and washed with aqueous ammonium hydroxide (5M; 800 mL), dried over magnesium sulfate, and evaporated to dryness under reduced pressure. The involatile residue was purified by chromatography on silica gel [elution gradient 1% to 7% of ethyl acetate in hexanes] to give the title compound (8.538 g, 28%), as a colorless amorphous solid.

¹H-NMR (DMSO-d₆) (300 MHz) δ 8.05 (d, 1H); 8.40 (dd, 1H); 8.95 (d, 1H).


10

5-Bromo-2-tetrazol-5-ylpyridine



A mixture of 3-bromo-6-cyano-pyridine (2 g, 10.9 mmol), sodium azide (0.85 g, 13 mmol), and ammonium chloride (0.59 g, 11 mmol) in *N,N*-dimethylformamide (20 mL) was heated for 1 h at 120 °C. The reaction mixture was diluted with ethyl acetate (~100 mL) and the product was isolated by filtration and then washed with ethyl acetate to give the title compound, an off-white amorphous solid which was used in the next step without further purification.

20 5-Bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine and 5-bromo-2-(1-methyl-1H-tetrazol-5-yl)pyridine



5-Bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine and 5-bromo-2-(1-methyl-1H-tetrazol-5-yl)pyridine were prepared according to the procedure described by Dong A Pharmaceuticals (WO 01/94342).

A mixture of 6.5 g unpurified 5-bromo-2-tetrazol-5-ylpyridine [Dong A Pharmaceuticals (WO 01/94342)] (~28 mmol) and sodium hydroxide (9 g, 125 mmol) in dry DMF was evaporated to dryness under reduced pressure. A stirred solution of the involatile residue in dry DMF (50 mL) was treated dropwise at ice-bath temperature with iodomethane (3.0 mL, 48 mmol). The


stirred reaction mixture was allowed to warm and then maintained at room temperature for 2 hours. The reaction mixture was partitioned between iced water and ethyl acetate. The organic phase was washed with water, dried over magnesium sulfate, and then evaporated under reduced pressure to give a residue that was purified by chromatography on silica gel

5 [elution with dichloromethane:ethyl acetate (60:1)] to give:

1. 5-bromo-2-(1-methyl-1*H*-tetrazol-5-yl)pyridine (1.397 g), a colorless solid, (TLC: silica-gel, hexanes:ethyl acetate (4:1), R_f : 0.3), ¹H-NMR (DMSO-d₆) (300 MHz) δ: 4.38 (s, 3H); 8.17 (d, 1H); 8.35 (dd, 1H); 8.96 (d, 1H).
2. 5-bromo-2-(2-methyl-2*H*-tetrazol-5-yl)pyridine (1.07 g), a colorless solid, (TLC: silica-gel, hexanes:ethyl acetate (4:1), R_f: 0.1). ¹H-NMR (DMSO-d₆) (300 MHz) δ: 4.46 (s, 3H); 8.09 (d, 1H); 8.28 (dd, 1H); 8.88 (d, 1H).

Structure assignment based on nmr HMBC (Heteronuclear Multiple Bond Correlation) experiments, in which long range coupling of the protons of CH₃ to the C5 of the tetrazole ring is observed in the 1-methyl-1*H*-isomer of R_f 0.3, but not in the 2-methyl-2*H*-isomer of R_f 0.1). The compound referred to as 5-bromo-2-(1-methyl-1*H*-tetrazol-5-yl)pyridine is thus the isomer of R_f 0.3 and the compound referred to as 5-bromo-2-(2-methyl-2*H*-tetrazol-5-yl)pyridine is thus the isomer of R_f 0.1

20 Example 2: (5*R*)-3-(3-Fluoro-4-(6-(2-methyl-2*H*-tetrazol-5-yl)pyrid-3-yl)phenyl)-5-(4-fluoromethyl-1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



A mixture of (5*R*)-3-(3-fluoro-4-iodophenyl)-5-(4-fluoromethyl-1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (1.5 g, 3.57 mmol), *bis*(pinacolato)diboron (2.26 g, 8.9 mmol), and potassium acetate (1.22 g, 12.5 mmol) in dimethylsulfoxide (15 mL) was treated with dichloro[1,1']*bis*(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (261 mg, 10 mol %) and allowed to react as described for Example 1. The reaction mixture was purified by chromatography on silica gel [elution with hexanes:ethyl acetate (3:2)] to give a mixture of (5*R*)-3-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-5-(4-fluoromethyl-1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one with the corresponding boronic acid (562 mg, ~37%) that was sufficiently pure for further use.

A mixture of a portion of the mixture of boronate ester and boronic acid prepared above (337 mg, 0.8 mmol), 5-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine (175 mg, 0.73 mmol), and potassium carbonate (504 mg, 3.65 mmol) in *N,N*-dimethylformamide:water (10 mL, 7:1) was treated with tetrakis(triphenylphosphine) palladium (0) (84 mg, 10 mol %) and allowed to react as described for Example 1. The reaction mixture was purified by chromatography on silica gel [elution with ethyl acetate:hexanes (1:2)] to give the product as a colorless amorphous solid (180 mg, 49 %).


MS (ESP): 454.45 (MH^+) for $C_{20}H_{17}F_2N_9O_2$

1H -NMR (DMSO- d_6) δ : 3.98 (dd, 1H); 4.32 (dd, 1H); 4.47 (s, 3H); 4.88 (m, 2H); 5.19 (m, 1H); 5.46 (d, 2H, J_{HF} 48 Hz); 7.45 (m, 1H); 7.63 (m, 1H); 7.75 (m, 1H); 8.15-8.24 (m, 2H); 8.38 (d, 1H); 8.93 (s, 1H).

The intermediates for Example 2 were prepared as follows:

(5R)-3-(3-Fluoro-4-iodophenyl)-5-(4-hydroxymethyl-1H-1,2,3-triazol-1-ylmethyl)-

1,3-oxazolidin-2-one




A mixture of (5R)-3-(3-fluoro-4-iodophenyl)-5-azidomethyl-1,3-oxazolidin-2-one (10 g, 28 mmol) and propargyl alcohol (3.2 mL, 56 mmol) in acetonitrile (80 mL) was treated with CuI (526 mg, 2.8 mmol) and then stirred overnight. The solidified reaction mixture was extracted with ethyl acetate:acetonitrile, washed with water, and dried over magnesium sulfate, and then evaporated under reduced pressure to give a crude product sufficiently pure for further use (12.3 g, quantitative).

MS (ESP): 419.13 (MH^+) for $C_{13}H_{12}FIN_4O_3$

1H -NMR (DMSO- d_6) δ : 3.88 (dd, 1H); 4.23 (dd, 1H); 4.51 (d, 2H); 4.80 (m, 2H); 5.14 (m, 1H); 5.22 (dd, 1H); 7.16 (m, 1H); 7.51 (m, 1H); 7.83 (m, 1H); 8.01 (d, 1H).

(5R)-3-(3-Fluoro-4-iodophenyl)-5-(4-bromomethyl-1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one




A stirred mixture of (5R)-3-(3-fluoro-4-iodophenyl)-5-(4-hydroxymethyl-1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (14.7 g, 35.1 mmol) and carbon tetrabromide (12.16 g, 36.7 mmol) in dichloromethane (1 L) was treated at 0°C with triphenylphosphine (12.34 g, 61.2 mmol). The reaction mixture was stirred for 30 minutes at 0°C and then at room temperature overnight. The reaction mixture was applied onto a silica-gel column and eluted with hexanes:ethyl acetate (1:1) and then with ethyl acetate:methanol (95:5) to give a product that was further purified by recrystallization from ethyl acetate to give the title compound as a colorless solid (14 g).

MS (ESP): 482.69 (MH^+ for Br^{81}) for $C_{13}H_{11}BrFIN_4O_2$

1H -NMR (DMSO- d_6) δ : 3.87 (dd, 1H); 4.23 (dd, 1H); 4.74 (s, 2H); 4.81 (m, 2H); 5.12 (m, 1H); 7.14 (m, 1H); 7.49 (m, 1H); 7.81 (m, 1H); 8.22 (d, 1H).

(5R)-3-(3-fluoro-4-iodophenyl)-5-[(4-fluoromethyl-1H-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one




A mixture of (5R)-3-(3-fluoro-4-iodophenyl)-5-(4-bromomethyl-1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (6.94 g, 14.4 mmol), potassium fluoride (4.19 g, 72.1 mmol), and 1-butyl-3-methylimidazolium tetrafluoroborate (18.4 mL) in acetonitrile (250 mL) and water (1.5 mL) was heated to 90 °C overnight. The reaction mixture was diluted with ethyl acetate, washed with water, dried over magnesium sulfate, and evaporated to dryness. The involatile residue was purified by chromatography on silica gel [elution with ethyl acetate] gave the title compound as an off-white amorphous solid (2.7 g, 45 %).

MS (ESP): 421.34 (MH^+) for $C_{13}H_{11}F_2IN_4O_2$

1H -NMR (DMSO- d_6) δ : 3.88 (dd, 1H); 4.23 (dd, 1H); 4.84 (m, 2H); 5.14 (m, 1H); 5.45

(d, 2H, $J_{H,F}$ 52 Hz); 7.14 (m, 1H); 7.49 (m, 1H); 7.81 (m, 1H); 8.34 (d, 1H).

Example 3: (5R)-3-(3-Fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyrid-3-yl)phenyl)-5-(4-chloro-1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one




5 A mixture of (5R)-3-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-5-(4-chloro-1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (300 mg, 0.71 mmol), 5-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine (170 mg, 0.71 mmol), and sodium carbonate (226 mg, 2.13 mmol) in *N,N*-dimethylformamide:water (5 mL, 10:1) was degassed, flushed with
10 nitrogen, and treated with *tetrakis*(triphenylphosphine)palladium (0) (82 mg, 10 mol %). The reaction mixture was heated at 70 °C for 3 hours, cooled to room temperature, and evaporated to dryness under reduced pressure. The involatile residue was purified by chromatography on silica gel [elution with dichloromethane:*N,N*-dimethylformamide (25:1 to 20:1)]. The product
15 fraction was concentrated to a small volume (~3 mL) and treated with dichloromethane (5 mL) and hexanes (15 mL) to precipitate the product as a colorless amorphous solid (229 mg, 71 %).

MS (ESP): 456.27 (MH^+) for $C_{19}H_{15}FN_9O_2$

1H -NMR (DMSO- d_6) δ : 3.98 (dd, 1H); 4.32 (dd, 1H); 4.47 (s, 3H); 4.86 (m, 2H); 5.19 (m, 1H); 7.46 (m, 1H); 7.63 (m, 1H); 7.76 (m, 1H); 8.15-8.27 (m, 2H); 8.47 (s, 1H); 8.93
20 (s, 1H).

The intermediates for Example 3 were prepared as follows:

Ethenesulfonyl chloride




25 A stirred solution of 2-chloroethanesulfonyl chloride (50 g, 0.307 mol) in dry ether (400 mL) was treated at -60 °C to -50 °C under an atmosphere of nitrogen with a solution of 2,6-lutidine (42.2 mL, 0.36 mol) in dry ether (60 mL) and then with a further portion of dry ether (200 mL). The stirred reaction mixture was allowed to warm to room temperature, cooled to 0 °C and then treated slowly with dilute aqueous sulfuric acid (1%; 125 mL). The

etheral phase was separated, washed with dilute aqueous sulfuric acid (1%; 125 mL) and brine (2 x 120 mL), dried over magnesium sulfate, and concentrated under reduced pressure (500 mmHg) to give a crude oil that was purified by distillation to give ethenesulfonyl chloride (C.S. Rondestveldt, *J. Amer. Chem. Soc.*, **76**, 1954, 1926) (24.6 g, 63%),

5 b.p. 27.2°C / 0.2mmHg.

$^1\text{H-nmr}$ (CDCl_3) δ 7.20 (dd, $J = 16.2$ and 9.4 Hz, 1H), 6.55 (dd, $J = 16.2$ and 1.7 Hz, 1H), and 6.24 (dd, $J = 9.4$ and 1.7 Hz, 1H).

1,2-Dichloroethanesulfonyl chloride




10

A stirred solution of chlorine in a solution of ethenesulfonyl chloride (32 g, 0.25 mol) in carbon tetrachloride was irradiated at about room temperature (200W light) for 5 h. The reaction mixture was concentrated under reduced pressure (50 mmHg) and the involatile residue was fractionally distilled to give 1,2-dichloroethanesulfonyl chloride (Goldstein *et al.*

15 *Zh. Obshch. Khim.*, **28**, 1958, 2107) (15.5 g, 31%), b.p. 75 °C / 0.7mmHg..

$^1\text{H-nmr}$ (CDCl_3) δ 5.29 (dd, $J = 8.9$ and 3.3 Hz, 1H), 4.40 (dd, $J = 12.4$ and 3.3 Hz, 1H), and 3.97 (dd, $J = 12.4$ and 8.9 Hz, 1H).


1-Chloro-1-ethenesulfonyl chloride



20 A stirred solution of 1,2-dichloroethanesulfonyl chloride (14.54 g, 73.62 mmol) in dry ether (140 mL) was treated at -60 °C to -50 °C under an atmosphere of nitrogen with 2,6-lutidine (10.30 mL, 88.34 mmol). The stirred reaction mixture was allowed to warm to room temperature, cooled to 0 °C and then treated slowly with dilute aqueous sulfuric acid (1%; 50 mL). The ethereal phase was separated, washed with dilute aqueous sulfuric acid (1%; 2 x 60 mL) and brine (3 x 60 mL), dried over magnesium sulfate, and concentrated under reduced pressure (60 mmHg) to give an oil that was purified by distillation to give 1-chloro-1-ethenesulfonyl chloride (7.2 g, 61%), b.p. 26 °C / 2mmHg.

$^1\text{H-nmr}$ (CDCl_3) δ 6.70 (d, $J = 3.8$ Hz, 1H) and 6.22 (d, $J = 3.8$ Hz, 1H).

(5R)-3-(3-Fluoro-4-iodophenyl)-5-(4-chloro-1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one




A stirred mixture of (5R)-3-(3-fluoro-4-iodophenyl)-5-azidomethyl-1,3-oxazolidin-2-one (1 g, 28 mmol) and 1-chloro-1-ethenesulfonyl chloride (1 g, 6.2 mmol) was heated in a pressure tube at 80 °C for one hour. The reaction mixture was cooled to room temperature, diluted with chloroform (15 mL), and heated at 80 °C for an additional 4 hours. The reaction mixture was cooled to room temperature and the precipitate was collected by filtration and washed with little dichloromethane to yield the title compound as a colorless amorphous solid (725 mg, 62%).

MS (ESP): 423.3 (MH⁺) for C₁₂H₉FIN₄O₂

¹H-NMR (DMSO-d₆) δ: 3.89 (dd, 1H); 4.22 (dd, 1H); 4.82 (m, 2H); 5.15 (m, 1H); 7.15 (m, 1H); 7.49 (m, 1H); 7.82 (m, 1H); 8.44 (s, 1H).

(5R)-3-(3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-5-(4-chloro-1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



A mixture of (5R)-3-(3-fluoro-4-iodophenyl)-5-(4-chloro-1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (725 mg, 1.7 mmol), bis(pinacolato)diboron (1.09 g, 4.3 mmol), and potassium acetate (590 mg, 6 mmol) in dimethylsulfoxide (10 mL) was treated with dichloro[1,1']bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (90 mg, 0.11 mmol) and allowed to react as described for Example 1. After 45 minutes the reaction mixture was cooled to room temperature, diluted with ethyl acetate and washed with aqueous ammonium chloride solution. The aqueous layer was extracted two times with ethyl acetate and the combined organic layers were washed with water, dried over sodium sulfate, and evaporated to dryness. The involatile residue was purified by chromatography on silica gel [elution with with hexanes:acetone (2:1)] and further purified by precipitation from dichloromethane with hexanes to give the product as a colorless amorphous solid (590 mg


81 %) that was sufficiently pure for subsequent reactions.

MS (ESP): 423 (MH^+) for $\text{C}_{18}\text{H}_{21}\text{BFN}_4\text{O}_4$

$^1\text{H-NMR}$ (DMSO-d_6) δ : 1.28 (s, 12H); 3.92 (dd, 1H); 4.24 (dd, 1H); 4.83 (m, 2H); 5.16 (m, 1H); 7.30 (m, 1H); 7.39 (m, 1H); 7.63 (m, 1H); 8.45 (s, 1H).



Claims

1. A compound of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof,



(I)

wherein C is selected from D and E,



wherein in D and E the phenyl ring is attached to the oxazolidinone in (I);

R_{1b} is HET1 or HET2, wherein

i) HET1 is an N-linked 5-membered, fully or partially unsaturated heterocyclic ring,

containing either (i) 1 to 3 further nitrogen heteroatoms or (ii) a further heteroatom selected

from O and S together with an optional further nitrogen heteroatom; which ring is optionally

substituted on a C atom, other than a C atom adjacent to the linking N atom, by an oxo or

thioxo group; and/or which ring is optionally substituted on any available C atom, other than a

C atom adjacent to the linking N atom, by a substituent selected from RT as hereinafter

defined and/or on an available nitrogen atom, other than a N atom adjacent to the linking N

atom, (provided that the ring is not thereby quaternised) by (1-4C)alkyl;

ii) HET2 is an N-linked 6-membered di-hydro-heteroaryl ring containing up to three nitrogen heteroatoms in total (including the linking heteroatom), which ring is substituted on a suitable

C atom, other than a C atom adjacent to the linking N atom, by oxo or thioxo and/or which

ring is optionally substituted on any available C atom, other than a C atom adjacent to the

linking N atom, by one or two substituents independently selected from RT as hereinafter

defined and/or on an available nitrogen atom, other than a N atom adjacent to the linking N

atom, (provided that the ring is not thereby quaternised) by (1-4C)alkyl;

RT is selected from a substituent from the group:

(RTa1) hydrogen, halogen, (1-4C)alkoxy, (2-4C)alkenyloxy, (2-4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, (1-4C)alkylthio, amino, azido, cyano

5 and nitro; or

(RTa2) (1-4C)alkylamino, di-(1-4C)alkylamino, and (2-4C)alkenylamino;

or RT is selected from the group

(RTb1) (1-4C)alkyl group which is optionally substituted by one substituent selected from hydroxy, (1-4C)alkoxy, (1-4C)alkylthio, cyano and azido; or

10 (RTb2) (1-4C)alkyl group which is optionally substituted by one substituent selected from (2-4C)alkenyloxy, (3-6C)cycloalkyl, and (3-6C)cycloalkenyl;

or RT is selected from the group

(RTc) a fully saturated 4-membered monocyclic ring containing 1 or 2 heteroatoms independently selected from O, N and S (optionally oxidised), and linked via a ring nitrogen

15 or carbon atom;

and wherein at each occurrence of an RT substituent containing an alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl moiety in (RTa1) or (RTa2), (RTb1) or (RTb2), or (RTc) each such moiety is optionally substituted on an available carbon atom with one, two, three or more substituents independently selected from F, Cl, Br, OH and CN;

20

R_{2a} and R_{6a} are independently selected from H, CF₃, OMe, SMe, Me and Et;

R_{2b} and R_{6b} are independently selected from H, F, Cl, CF₃, OMe, SMe, Me and Et;

R_{3a} is selected from H, (1-4C)alkyl, cyano, Br, F, Cl, OH, (1-4C)alkoxy, -S(O)_n(1-4C)alkyl (wherein n = 0, 1, or 2), amino, (1-4C)alkylcarbonylamino, nitro, -CHO, -CO(1-4C)alkyl,

25 -CONH₂ and -CONH(1-4C)alkyl;

R₄ is selected from R_{4a} and R_{4b} wherein

R_{4a} is selected from azido, -NR₇R₈, OR₁₀, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)cycloalkyl, -(CH₂)_k-R₉, AR₁, AR₂, (1-4C)acyl, -CS(1-4C)alkyl, -C(=W)NR_vR_w [wherein W is O or S,

30 R_v and R_w are independently H, or (1-4C)alkyl], -C(=O)_i-R₆, -COO(1-4C)alkyl, -C=OAR₁,

-C=OAR₂, -COOAR₁, S(O)_n(1-4C)alkyl (wherein n = 1 or 2), -S(O)_pAR₁, -S(O)_pAR₂ and -C(=S)O(1-4C)alkyl; wherein any (1-4C)alkyl chain may be optionally substituted by

(1-4C)alkyl, cyano, hydroxy or halo; p = 0, 1 or 2;

R4b is selected from HET-3;

R6 is selected from hydrogen, (1-4C)alkoxy, amino, (1-4C)alkylamino and hydroxy(1-4C)alkylamino;

k is 1 or 2;

5 l is 1 or 2;

R7 and R8 are independently selected from H and (1-4C)alkyl, or wherein R7 and R8 taken together with the nitrogen to which they are attached can form a 5-7 membered ring optionally with an additional heteroatom selected from N, O, S(O)_n (wherein n = 1 or 2) in place of 1 carbon atom of the so formed ring; wherein the ring may be optionally substituted

10 by one or two groups independently selected from (1-4C)alkyl, (1-4C)cycloalkyl, (1-4C)acyl, -COO(1-4C)alkyl, S(O)_n(1-4C)alkyl (wherein n = 1 or 2), AR1, AR2, , -C=OAR1, -C=OAR2, -COOAR1, -CS(1-4C)alkyl, -C(=S)O(1-4C)alkyl, -C(=W)NR_vR_w [wherein W is O or S, R_v and R_w are independently H, or (1-4C)alkyl], -S(O)_pAR1 and -S(O)_pAR2; wherein any (1-4C)alkyl, (1-4C)cycloalkyl or (1-4C)acyl group may be optionally substituted
15 (except on a carbon atom adjacent to a heteroatom) by one or two substituents selected from (1-4C)alkyl, cyano, hydroxy, halo, amino, (1-4C)alkylamino and di(1-4C)alkylamino; p = 0, 1 or 2;

R9 is independently selected from R9a to R9d below:


R9a: AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4, AR4a, CY1, CY2;

20 R9b: cyano, carboxy, (1-4C)alkoxycarbonyl, -C(=W)NR_vR_w [wherein W is O or S, R_v and R_w are independently H, or (1-4C)alkyl and wherein R_v and R_w taken together with the amide or thioamide nitrogen to which they are attached can form a 5-7 membered ring optionally with an additional heteroatom selected from N, O, S(O)_n in place of 1 carbon atom of the so formed ring; wherein when said ring is a piperazine ring, the ring may be optionally
25 substituted on the additional nitrogen by a group selected from (1-4C)alkyl, (1-4C)cycloalkyl, (1-4C)acyl, -COO(1-4C)alkyl, S(O)_n(1-4C)alkyl (wherein n = 1 or 2); -COOAR1, -CS(1-4C)alkyl and -C(=S)O(1-4C)alkyl; wherein any alkyl, acyl or cycloalkyl may itself optionally be substituted by cyano, hydroxy or halo)], ethenyl, 2-(1-4C)alkylethenyl, 2-cyanoethenyl, 2-cyano-2-((1-4C)alkyl)ethenyl, 2-nitroethenyl, 2-nitro-2-
30 ((1-4C)alkyl)ethenyl, 2-((1-4C)alkylaminocarbonyl)ethenyl, 2-((1-4C)alkoxycarbonyl)ethenyl, 2-(AR1)ethenyl, 2-(AR2)ethenyl, 2-(AR2a)ethenyl;

R9c: (1-6C)alkyl

{optionally substituted by one or more groups (including geminal disubstitution) each


- independently selected from hydroxy, (1-10C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkylcarbonyl, phosphoryl [-O-P(O)(OH)₂], and mono- and di-(1-4C)alkoxy derivatives thereof], phosphinyl [-O-P(OH)₂ and mono- and di-(1-4C)alkoxy derivatives thereof], and amino; and/or optionally substituted by one group
- 5 selected from carboxy, phosphonate [phosphono, -P(O)(OH)₂, and mono- and di-(1-4C)alkoxy derivatives thereof], phosphinate [-P(OH)₂ and mono- and di-(1-4C)alkoxy derivatives thereof], cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-6C)alkanoylamino-, (1-4C)alkoxycarbonylamino-, N-(1-4C)alkyl-
- 10 N-(1-6C)alkanoylamino-, -C(=W)NR_vR_w [wherein W is O or S, R_v and R_w are as hereinbefore defined], (=NOR_v) wherein R_v is as hereinbefore defined, (1-4C)alkylS(O)_pNH-, (1-4C)alkylS(O)_p-((1-4C)alkyl)N-, fluoro(1-4C)alkylS(O)_pNH-, fluoro(1-4C)alkylS(O)_p((1-4C)alkyl)N-, (1-4C)alkylS(O)_q-, CY1, CY2, AR1, AR2, AR3, AR1-O-, AR2-O-, AR3-O-, AR1-S(O)_q-, AR2-S(O)_q-, AR3-S(O)_q-, AR1-NH-, AR2-NH-,
- 15 AR3-NH- (p is 1 or 2 and q is 0, 1 or 2), and also AR2a, AR2b, AR3a and AR3b versions of AR2 and AR3 containing groups}; wherein any (1-4C)alkyl present in any substituent on R_{9c} may itself be substituted by one or two groups independently selected from cyano, hydroxy, halo, amino, (1-4C)alkylamino and di(1-4C)alkylamino, provided that such a substituent is not on a carbon adjacent to a heteroatom atom if present;
- 20 R_{9d}: R₁₄C(O)O(1-6C)alkyl- wherein R₁₄ is AR1, AR2, (1-4C)alkylamino, benzyloxy-(1-4C)alkyl or (1-10C)alkyl {optionally substituted as defined for (R_{9c})}; R₁₀ is selected from hydrogen, R_{9c} (as hereinbefore defined), (1-4C)acyl and (1-4C)alkylsulfonyl;
- HET-3 is selected from:
- 25 a) a 5-membered heterocyclic ring containing at least one nitrogen and/or oxygen in which any carbon atom is a C=O, C=N, or C=S group, wherein said ring is of the formula HET3-A to HET3-E below:



HET3-A

HET3-B


HET3-C




HET3-D

HET3-E


b) a carbon-linked 5- or 6-membered heteroaromatic ring containing 1, 2, 3, or 4 heteroatoms independently selected from N, O and S selected from HET3-F to HET3-Y below:




HET3-F




HET3-G




HET3-H




HET3-I




HET3-J




HET3-K




HET3-L




HET3-M




HET3-N




HET3-O




HET3-P




HET3-Q




HET3-R




HET3-S




HET3-T



HET3-U




HET3-V



HET3-W




HET3-X




HET3-Y

c) a nitrogen-linked 5- or 6-membered heteroaromatic ring containing 1, 2, 3, or 4 heteroatoms independently selected from N, O and S selected from HET3-Z to HET3-AH


5 below:




HET3-Z




HET3-AA




HET3-AB




HET3-AC




HET3-AD




HET3-AE



HET3-AF



HET3-AG



HET3-AH

wherein in HET-3, R_{1a} is a substituent on carbon;

R_{1a} is independently selected from R_{1a1} to R_{1a5} below:

R_{1a1}: AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4, AR4a, CY1, CY2;

R_{1a2}: cyano, carboxy, (1-4C)alkoxycarbonyl, -C(=W)NR_vR_w [wherein W is O or S, R_v and R_w are independently H, or (1-4C)alkyl and wherein R_v and R_w taken together with the

- 5 amide or thioamide nitrogen to which they are attached can form a 5-7 membered ring optionally with an additional heteroatom selected from N, O, S(O)_n in place of 1 carbon atom of the so formed ring; wherein when said ring is a piperazine ring, the ring may be optionally substituted on the additional nitrogen by a group selected from (1-4C)alkyl, (1-4C)cycloalkyl, (1-4C)acyl, -COO(1-4C)alkyl, S(O)_n(1-4C)alkyl (wherein n = 1 or 2), -COOAR1, 10 -CS(1-4C)alkyl) and -C(=S)O(1-4C)alkyl; wherein any (1-4C)alkyl, (1-4C)acyl and (1-4C)cycloalkyl substituent may itself be substituted by cyano, hydroxy or halo, provided that, such a substituent is not on a carbon adjacent to a nitrogen atom of the piperazine ring], ethenyl, 2-(1-4C)alkylethenyl, 2-cyanoethenyl, 2-cyano-2-((1-4C)alkyl)ethenyl, 2-nitroethenyl, 2-nitro-2-((1-4C)alkyl)ethenyl, 2-((1-4C)alkylaminocarbonyl)ethenyl, 15 2-((1-4C)alkoxycarbonyl)ethenyl, 2-(AR1)ethenyl, 2-(AR2)ethenyl, 2-(AR2a)ethenyl;

R_{1a3}: (1-10C)alkyl


- {optionally substituted by one or more groups (including geminal disubstitution) each independently selected from hydroxy, (1-10C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkylcarbonyl, phosphoryl [-O-P(O)(OH)₂, 20 and mono- and di-(1-4C)alkoxy derivatives thereof], phosphiryl [-O-P(OH)₂ and mono- and di-(1-4C)alkoxy derivatives thereof], and amino; and/or optionally substituted by one group selected from carboxy, phosphonate [phosphono, -P(O)(OH)₂, and mono- and di-(1-4C)alkoxy derivatives thereof], phosphinate [-P(OH)₂ and mono- and di-(1-4C)alkoxy derivatives thereof], cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy- 25 (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-6C)alkanoylamino-, (1-4C)alkoxycarbonylamino-, N-(1-4C)alkyl- N-(1-6C)alkanoylamino-, -C(=W)NR_vR_w [wherein W is O or S, R_v and R_w are independently H, or (1-4C)alkyl and wherein R_v and R_w taken together with the amide or thioamide nitrogen to which they are attached can form a 5-7 membered ring optionally with 30 an additional heteroatom selected from N, O, S(O)_n in place of 1 carbon atom of the so formed ring; wherein when said ring is a piperazine ring, the ring may be optionally substituted on the additional nitrogen by a group selected from (1-4C)alkyl, (1-4C)cycloalkyl, (1-4C)acyl, -COO(1-4C)alkyl, S(O)_n(1-4C)alkyl (wherein n = 1 or 2), -COOAR1,

- CS(1-4C)alkyl and -C(=S)O(1-4C)alkyl], (=NOR_v) wherein R_v is as hereinbefore defined, (1-4C)alkylS(O)_pNH-, (1-4C)alkylS(O)_p((1-4C)alkyl)N-, fluoro(1-4C)alkylS(O)_pNH-, fluoro(1-4C)alkylS(O)_p((1-4C)alkyl)N-, (1-4C)alkylS(O)_q-, CY1, CY2, AR1, AR2, AR3, AR1-O-, AR2-O-, AR3-O-, AR1-S(O)_q-, AR2-S(O)_q-, AR3-S(O)_q-, AR1-NH-, AR2-NH-, AR3-NH- (p is 1 or 2 and q is 0, 1 or 2), and also AR2a, AR2b, AR3a and AR3b versions of AR2 and AR3 containing groups}; wherein any (1-4C)alkyl, (1-4C)acyl and (1-4C)cycloalkyl present in any substituent on R_{1a3} may itself be substituted by one or two groups independently selected from cyano, hydroxy, halo, amino, (1-4C)alkylamino and di(1-4C)alkylamino, provided that such a substituent is not on a carbon adjacent to a heteroatom atom if present;
- R_{1a4}: R₁₄C(O)O(1-6C)alkyl- wherein R₁₄ is AR1, AR2, AR2a, AR2b, (1-4C)alkylamino, benzyloxy-(1-4C)alkyl or (1-10C)alkyl {optionally substituted as defined for (R_{1a3})};
- R_{1a5}: F, Cl, hydroxy, mercapto, (1-4C)alkylS(O)_p- (p = 0, 1 or 2), -NR₇R₈ (wherein R₇ and R₈ are as hereinbefore defined) or -OR₁₀ (where R₁₀ is as hereinbefore defined);
- m is 0, 1 or 2;
- R₂₁ is selected from hydrogen, methyl [optionally substituted with cyano, trifluoromethyl, -C=WNR_vR_w (where W, R_v and R_w are as hereinbefore defined for R_{1a3}), (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, CY1, CY2, AR1, AR2, AR2a, AR2b (not linked through nitrogen) or AR3], (2-10C)alkyl [optionally substituted other than on a carbon attached to the HET-3 ring nitrogen with one or two groups independently selected from the optional substituents defined for R_{1a3}] and R₁₄C(O)O(2-6C)alkyl-, wherein R₁₄ is as defined hereinbefore for R_{1a4} and wherein R₁₄C(O)O group is attached to a carbon other than the carbon attached to the HET-3 ring nitrogen;
- R₂₂ is cyano, -COR₁₂, -COOR₁₂, -CONHR₁₂, -CON(R₁₂)(R₁₃), -SO₂R₁₂ (provided that R₁₂ is not hydrogen), -SO₂NHR₁₂, -SO₂N(R₁₂)(R₁₃) or NO₂, wherein R₁₂ and R₁₃ are as defined hereinbelow;
- R₁₂ and R₁₃ are independently selected from hydrogen, phenyl (optionally substituted with one or more substituents selected from halogen, (1-4C)alkyl and (1-4C)alkyl substituted with one, two, three or more halogen atoms) and (1-4C)alkyl (optionally substituted with one, two, three or more halogen atoms), or for any N(R₁₂)(R₁₃) group, R₁₂ and R₁₃ may be taken together with the nitrogen to which they are attached to form a 5-7 membered ring optionally with an additional heteroatom selected from N, O, S(O)_n in place of 1 carbon atom of the so


- formed ring; wherein the ring may be optionally substituted by one or two groups independently selected from (1-4C)alkyl (optionally substituted on a carbon not adjacent to the nitrogen by cyano, hydroxy or halo), (1-4C)cycloalkyl, (1-4C)acyl, -COO(1-4C)alkyl, S(O)_n(1-4C)alkyl (wherein n = 1 or 2), AR1, AR2, , -C=OAR1, -C=OAR2, -COOAR1,
- 5 -CS(1-4C)alkyl, -C(=S)O(1-4C)alkyl, -C(=W)NR_vR_w [wherein W is O or S, R_v and R_w are independently H, or (1-4C)alkyl], -S(O)_pAR1 and -S(O)_pAR2; wherein any (1-4C)alkyl chain may be optionally substituted by (1-4C)alkyl, cyano, hydroxy or halo; p = 0,1 or 2;
- AR1 is an optionally substituted phenyl or optionally substituted naphthyl;
- AR2 is an optionally substituted 5- or 6-membered, fully unsaturated monocyclic heteroaryl
- 10 ring containing up to four heteroatoms independently selected from O, N and S (but not containing any O-O, O-S or S-S bonds), and linked via a ring carbon atom, or a ring nitrogen atom if the ring is not thereby quaternised;
- AR2a is a partially hydrogenated version of AR2, linked via a ring carbon atom or linked via a ring nitrogen atom if the ring is not thereby quaternised;
- 15 AR2b is a fully hydrogenated version of AR2, linked via a ring carbon atom or linked via a ring nitrogen atom;
- AR3 is an optionally substituted 8-, 9- or 10-membered, fully unsaturated bicyclic heteroaryl ring containing up to four heteroatoms independently selected from O, N and S (but not containing any O-O, O-S or S-S bonds), and linked via a ring carbon atom in either of the
- 20 rings comprising the bicyclic system;
- AR3a is a partially hydrogenated version of AR3, linked via a ring carbon atom, or linked via a ring nitrogen atom if the ring is not thereby quaternised, in either of the rings comprising the bicyclic system;
- AR3b is a fully hydrogenated version of AR3, linked via a ring carbon atom, or linked via a
- 25 ring nitrogen atom, in either of the rings comprising the bicyclic system;
- AR4 is an optionally substituted 13- or 14-membered, fully unsaturated tricyclic heteroaryl ring containing up to four heteroatoms independently selected from O, N and S (but not containing any O-O, O-S or S-S bonds), and linked via a ring carbon atom in any of the rings comprising the tricyclic system;
- 30 AR4a is a partially hydrogenated version of AR4, linked via a ring carbon atom, or linked via a ring nitrogen atom if the ring is not thereby quaternised, in any of the rings comprising the tricyclic system;
- CY1 is an optionally substituted cyclobutyl, cyclopentyl or cyclohexyl ring;

- CY2 is an optionally substituted cyclopentenyl or cyclohexenyl ring;
 wherein; optional substituents on AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4, AR4a,
 CY1 and CY2 are (on an available carbon atom) up to three substituents independently
 selected from (1-4C)alkyl {optionally substituted by substituents selected independently from
 5 hydroxy, trifluoromethyl, (1-4C)alkyl S(O)_q- (q is 0, 1 or 2), (1-4C)alkoxy,
 (1-4C)alkoxycarbonyl, cyano, nitro, (1-4C)alkanoylamino, -CONR_vR_w or -NR_vR_w},
 trifluoromethyl, hydroxy, halo, nitro, cyano, thiol, (1-4C)alkoxy, (1-4C)alkanoyloxy,
 dimethylaminomethyleneaminocarbonyl, di(N-(1-4C)alkyl)aminomethylimino, carboxy,
 (1-4C)alkoxycarbonyl, (1-4C)alkanoyl, (1-4C)alkylSO₂amino, (2-4C)alkenyl {optionally
 10 substituted by carboxy or (1-4C)alkoxycarbonyl}, (2-4C)alkynyl, (1-4C)alkanoylamino, oxo
 (=O), thioxo (=S), (1-4C)alkanoylamino {the (1-4C)alkanoyl group being optionally
 substituted by hydroxy}, (1-4C)alkyl S(O)_q- (q is 0, 1 or 2) {the (1-4C)alkyl group being
 optionally substituted by one or more groups independently selected from cyano, hydroxy and
 (1-4C)alkoxy}, -CONR_vR_w or -NR_vR_w [wherein R_v is hydrogen or (1-4C)alkyl; R_w is
 15 hydrogen or (1-4C)alkyl];
 and further optional substituents on AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4,
 AR4a, CY1 and CY2 (on an available carbon atom), and also on alkyl groups (unless
 indicated otherwise) are up to three substituents independently selected from
 trifluoromethoxy, benzoylamino, benzoyl, phenyl {optionally substituted by up to three
 20 substituents independently selected from halo, (1-4C)alkoxy or cyano}, furan, pyrrole,
 pyrazole, imidazole, triazole, pyrimidine, pyridazine, pyridine, isoxazole, oxazole, isothiazole,
 thiazole, thiophene, hydroxyimino(1-4C)alkyl, (1-4C)alkoxyimino(1-4C)alkyl, halo-
 (1-4C)alkyl, (1-4C)alkanesulfonamido, -SO₂NR_vR_w [wherein R_v is hydrogen or (1-4C)alkyl;
 R_w is hydrogen or (1-4C)alkyl]; and
 25 optional substituents on AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4 and AR4a are (on an
 available nitrogen atom, where such substitution does not result in quaternization)
 (1-4C)alkyl, (1-4C)alkanoyl {wherein the (1-4C)alkyl and (1-4C)alkanoyl groups are
 optionally substituted by (preferably one) substituents independently selected from cyano,
 hydroxy, nitro, trifluoromethyl, (1-4C)alkyl S(O)_q- (q is 0, 1 or 2), (1-4C)alkoxy,
 30 (1-4C)alkoxycarbonyl, (1-4C)alkanoylamino, -CONR_vR_w or -NR_vR_w [wherein R_v is
 hydrogen or (1-4C)alkyl; R_w is hydrogen or (1-4C)alkyl]}, (2-4C)alkenyl, (2-4C)alkynyl,
 (1-4C)alkoxycarbonyl or oxo (to form an N-oxide).


2. A compound of the formula (I) as claimed in claim 1, or a pharmaceutically-acceptable salt, or an in-vivo hydrolysable ester thereof, wherein R1b is HET1 wherein HET1 is selected from the structures (Za) to (Zf),




(Za)




(Zb)




(Zc)



(Zd)



(Ze)



(Zf)

wherein u and v are independently 0 or 1 and RT selected from:

- (a) hydrogen;
- (b) halogen;
- (c) cyano;
- (d) (1-4C)alkyl;
- (e) monosubstituted (1-4C)alkyl;
- (f) disubstituted (1-4C)alkyl, and
- (g) trisubstituted (1-4C)alkyl.

3. A compound of the formula (I) as claimed in claim 1 or claim 2, or a pharmaceutically-acceptable salt, or an in-vivo hydrolysable ester thereof, wherein R4 is R4b.

4. A compound of the formula (I) as claimed in any preceding claim or a pharmaceutically-acceptable salt, or an in-vivo hydrolysable ester thereof, wherein HET-3 is selected from HET3-T, HET3-V, HET3-Y and HET-3-W.


5. A compound of the formula (I) as claimed in any preceding claim, or a pharmaceutically-acceptable salt, or an in-vivo hydrolysable ester thereof, wherein HET-3 is selected from HET3-V and HET3-Y.

5 6. A compound of the formula (I) as claimed in any preceding claim, or a pharmaceutically-acceptable salt, or an in-vivo hydrolysable ester thereof, wherein R_{1a} is R_{1a3} .

7. A compound of the formula (I) as claimed in any preceding claim, or a
10 pharmaceutically-acceptable salt, or an in-vivo hydrolysable ester thereof, wherein group C is group D.

8. A compound of the formula (I) as claimed in any preceding claim, or a
15 pharmaceutically-acceptable salt, or an in-vivo hydrolysable ester thereof, wherein group C is group E.

9. A compound of the formula (IA) as claimed in any preceding claim, or a pharmaceutically-acceptable salt, or an in-vivo hydrolysable ester thereof.



(IA)

10. A pro-drug of a compound as claimed in any one of the previous claims.

25 11. A method for producing an antibacterial effect in a warm blooded animal which comprises administering to said animal an effective amount of a compound of the invention as claimed in any one of claims 1 to 10, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof.

12. A compound of the invention as claimed in any one of claims 1 to 10, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof, for use as a medicament.


13. The use of a compound of the invention as claimed in any one of claims 1 to 10, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof, in the manufacture of a medicament for use in the production of an antibacterial effect in a warm blooded animal.

14. A pharmaceutical composition which comprises a compound of the invention as claimed in any one of claims 1 to 10, or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, and a pharmaceutically-acceptable diluent or carrier.


15. A process for the preparation of a compound of formula (I) as claimed in claim 1 or pharmaceutically acceptable salts or in-vivo hydrolysable esters thereof, which process comprises one of processes (a) to (i);

a) by modifying a substituent in, or introducing a substituent into another compound of the invention;


b) by reaction of a molecule of a compound of formula (IIa) [wherein X is a leaving group useful in palladium coupling and A is either N or C-R_{3a}] with a molecule of a compound of formula (IIb) (wherein X' is a leaving group useful in palladium coupling) wherein X and X' are such that an aryl-aryl, heteroaryl-aryl, or heteroaryl-heteroaryl bond replaces the aryl-X (or heteroaryl-X) and aryl-X' (or heteroaryl-X') bonds; and X and X' are chosen to be different to lead to the desired cross-coupling products of formula (I);



c) by reaction of a heterobiaryl derivative (III) carbamate with an appropriately substituted oxirane to form an oxazolidinone ring;



(d) by reaction of a compound of formula (VI) :



5


where X is a replaceable substituent with a compound of the formula (VII):



wherein T-X' is HET1 or HET2 as herein above defined and X' is a replaceable C-linked substituent; wherein the substituents X and X' are chosen to be complementary pairs of substituents suitable as complementary substrates for coupling reactions catalysed by transition metals such as palladium(0);


10

(d(i)) by reaction catalysed by transition metals such as palladium(0) of a compound of formula (VIII):



15


wherein X is a replaceable substituent with a compound of the formula (IX);



20

(d(ii)) by reaction of a compound of formula (X):

- 79 -



(X)


X is a replaceable substituent with a compound of the formula (XI):

T-H


5

(XI)

wherein T-H is an amine R_7R_8NH , an alcohol $R_{10}OH$, or an azole with an available ring-NH group to give compounds (XIIa), (XIIb), or (XIIc) wherein in this instance A is nitrogen or C- R_{3a} and A' is nitrogen or carbon optionally substituted with one or more groups R_{1a} ;




(XIIa)




(XIIb)

10




(e) by reaction of a compound of formula (XIII):



(XIII)

15 wherein X1 and X2 here are independently optionally substituted heteroatoms drawn in combination from O, N, and S such that C(X1)X2 constitutes a substituent that is a carboxylic acid derivative substituent with a compound of the formula (XIV) and X3 and X4 are independently optionally substituted heteroatoms drawn in combination from O, N, and S:




(XIV)


20

and wherein one of C(X1)X2 and C(X3)X4 constitutes an optionally substituted hydrazide, thiohydrazide, or amidrazone, hydroximate, or hydroxamidine and the other one of C(X1)X2 and C(X3)X4 constitutes an optionally substituted acylating, thioacylating, or imidoylating agent such that C(X1)X2 and C(X3)X4 may be condensed together to form a 1,2,4-heteroatom 5-membered heterocycle containing 3 heteroatoms drawn in combination from O, N, and S, for instance thiadiazole;


(e (i)) by reaction of a compound of formula (XV):




10 wherein X₂ is a displaceable group with a source of azide anion to give a tetrazole (XVI);



or nitriles of formula (XVII)




15 may be reacted directly with azides to give tetrazoles (XVI, R_{1a} = H) that are subsequently alkylated with groups R_{1a} ≠ H to give tetrazoles (XVIIIa) and (XVIIIb);




20 (f) by reaction of a compound of formula (XIX):

- 81 -



with a compound of the formula (XX):



5


wherein one of C(X5)X6 and C(X7)X8 constitutes an optionally substituted alpha-(leaving-group-substituted)ketone, wherein the leaving group is for example a halo-group or an (alkyl or aryl)-sulfonyloxy-group, and the other one of C(X5)X6 and C(X7)X8 constitutes an optionally substituted amide, thioamide, or amidine, such that C(X5)X6 and C(X7)X8 are

10 groups that may be condensed together to form a 1,3-heteroatom 5-membered heterocycle containing 2 heteroatoms drawn in combination from O, N, and S, for instance thiazole;

(g) for HET as optionally substituted 1,2,3-triazoles, compounds of the formula (I), by cycloaddition via the azide (wherein e.g. Y in (II) is azide) to acetylenes, or to acetylene equivalents such as optionally substituted cyclohexa-1,4-dienes or optionally substituted


15 ethylenes bearing eliminatable substituents such as arylsulfonyl;

(h) for HET as 4-substituted 1,2,3-triazole compounds of formula (I), by reacting aminomethyloxazolidinones with 1,1-dihaloketone sulfonylhydrazones;




(i) for HET as 4-substituted 1,2,3-triazole compounds of formula (I), by reacting


20 azidomethyl oxazolidinones with terminal alkynes using Cu(I) to give 4-substituted 1,2,3-triazoles.



16. A process for the preparation of a compound of formula (I) as claimed in claim 1 or pharmaceutically acceptable salts or in-vivo hydrolysable esters thereof, wherein HET-1 is 4-halogenated 1,2,3-triazole comprising reacting azidomethyl oxazolidinones with halovinylsulfonyl chlorides at a temperature between 0 °C and 100 °C either neat or in an inert diluent.



17. A process according to claim 16 wherein the halovinylsulfonyl chloride is 1-chloro-1-ethenesulfonyl chloride.
18. The compound 1-chloro-1-ethenesulfonyl chloride.



19. The use of 1-chloro-1-ethenesulfonyl chloride in a cycloaddition reaction with an azide to form a 4-chloro-1,2,3-triazole.

20. The use of 1-chloro-1-ethenesulfonyl chloride with an azide derivative in a process to form a compound of the formula (I) wherein R1b is 4-chloro-1,2,3-triazole, or R4 is 4-chloro-HET3-AB.

PCT Application

GB0305091

